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ABSTRACT 
 
 Traumatic brain injury (TBI) has become an increasingly unmet clinical need due to 
intense military conflicts worldwide. Directly impacted brain cells suffer massive death, with 
neighboring cells succumbing to progressive neurodegeneration accompanied by inflammatory 
and other secondary cell death events. Subsequent neurodegenerative events may extend to 
normal areas beyond the core of injury, thereby exacerbating the central nervous system’s 
inflammatory response to TBI. Recently CD-36 (cluster of differentiation 36/fatty acid 
translocase (FAT), a class B scavenger receptor of modified low-density lipoproteins (mLDLs) in 
macrophages, has been implicated in lipid metabolism, atherosclerosis, oxidative stress, and 
tissue injury in cerebral ischemia, and in certain neurodegenerative diseases.  
Accordingly, we proposed that CD-36 has a pivotal role in the neuroinflammatory 
cascade that further contributes to the pathology of TBI. First, we explored the 
neuroinflammatory role of CD-36 after acute and chronic stages of TBI. Second, we employed a 
neuroinflammatory model to test the therapeutic effect of the soluble receptor of advanced end-
glycation product (sRAGE); previously shown to abrogate increased CD-36 expression in 
stroke. Third, we further examined ameliorating TBI related inflammation as a therapeutic 
pathway by combination of stem cell therapy and sRAGE. At acute stages of TBI, we observed 
brain co-localization of CD-36, monocyte chemoattractant protein 1 (MCP-1) and ionized 
calcium-binding adapter molecule 1 (Iba-1) on impacted cortical areas, significant increases of 
CD-36 and MCP-1 positive cells in the ipsilateral vs. contralateral hemispheres of TBI animals in 
acute, but no significant increases of Iba-1 expressing cells over time. In early acute stages of 
TBI immunoblotting showed overexpression of CD-36 in brain cortex when comparing ipsilateral 
vii 
and contralateral hemispheres vs. sham. Spleen CD-36 protein expression at acute post-TBI 
stages showed no significant difference between TBI and sham groups. In addition, 
immunohistochemistry revealed minimal CD-36 detection on the cortical area of impact on our 
chronic group. Spleen immunohistochemistry also showed co-localization of CD-36 and MCP-1 
in the red pulp of spleen in acute stages of TBI animals when compared to sham. Ongoing 
ischemic and hyperlipidemic rodent models suggest that infiltrating monocytes/macrophages 
from the periphery are the major source of CD-36 in the post-ischemic brain. Likewise, CD-36 
expressing monocytes in the spleen after TBI may suggest its role in peripheral immune 
response, which may exacerbates the inflammatory response after TBI. Therefore, CD-36 may 
play a key role as a pathological link between inflammation and TBI. 
Our results suggest an intimate involvement of CD-36 mediated inflammation in TBI, 
providing novel insights into the understanding of disease neuroinflammation and as a potent 
therapeutic target for TBI treatment. The critical timing (i.e., 24-48 hours) of CD-36 expression 
(from downregulation to upregulation) may signal the transition of functional effects of this 
immune response from pro-survival to cell death. This observed dynamic CD-36 expression 
also suggests the therapeutic window for TBI. The detection of CD-36 expression in brain areas 
proximal, as well as distal, to the site of impacted injury suggests its role in both acute and 
progressive evolution of TBI. CD-36 neuroinflammatory role has clinical relevance for treating 
patients who have suffered any TBI condition at acute and chronic stages. 
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CHAPTER 1 
INTRODUCTION 
 
1.1 Traumatic Brain Injury (TBI) 
Traumatic brain injury (TBI) results from a blast, an impact, or acceleration/deceleration 
to the head causing cognitive, psychological, neurological, and anatomical alterations in the 
brain. The brain suffers massive cell loss; neighboring cells undergo progressive 
neurodegeneration, inflammatory and cell death events. If subsequent incidents are not 
controlled on time, they may extend to normal areas beyond the core of injury; exacerbating the 
central nervous system’s immune response.  In recent years, TBI has drawn major public 
attention due to intense military conflict worldwide, sport related injuries, and among the toddler 
and senior populations. The CDC has also reported that about 53,000 people in the United 
States die from TBI-related causes every year (Coronado, Xu et al. 2011).This number does not 
include injuries seen at military or Veterans Health Administration health facilities. The National 
Institute of Neurological Disorders and Stroke (NINDS) reports every year approximately 1.4 
million people experience a TBI, 50,000 people die from head injury, 1 million head-injured 
people are treated in hospital emergency rooms, and approximately 230,000 people are 
hospitalized for TBI and survive. 
 According to the Defense and Veterans Brain Injury Center, in 2010 mild TBI accounted 
for over 77.8% of all TBI injuries sustained during combat. Whether injury results from a blast or 
a mechanical force to the head, it causes brain damage to different extents, with varying 
severity mainly in frontal and temporal lobes of the brain (Suh, Kolster et al. 2006; Kraus, 
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Susmaras et al. 2007; Hayashi, Kaneko et al. 2009). Equally debilitating, multiple exposures to 
minor events may also lead to long-term TBI symptomatic sequelae (Elder, Mitsis et al. 2010), 
such as cognitive, behavioral, and physical impairments, after TBI. It is estimated that 10% to 
20% of veterans returning from war have suffered a traumatic brain injury as a result of 
improvised explosive devices (Elder and Cristian 2009). Thus, urgent care and effective 
treatment should be available to TBI patients in the short and long term to treat their head 
injuries. More than 1.6 million soldiers have served in the wars in Iraq Operation Iraqi Freedom 
(OIF) and Afghanistan Operation Enduring Freedom (OEF) (Tanielian T. 2008.). In both military 
operations, TBI has been a major cause of mortality and morbidity, with blast-related injury the 
most common cause (Elder and Cristian 2009).As of today there is no effective therapy for TBI 
that has been approved by any health agency in the world. TBI defies conventional methods for 
diagnosis and therapy development because of its heterogeneity and complexity. Immediate 
conventional care and treatment to patients after TBI include: oxygen supply to the brain and 
the rest of the body, maintaining adequate blood flow, controlling blood pressure, and 
rehabilitation. Diagnosis and prognosis of a TBI patient with mild to moderate injuries may 
undergo imaging testing: skull and neck X-rays to check for bone fractures or spinal instability. 
In moderate to severe TBI cases, computed tomography (CT) scan is the signature. 
Pharmacological treatment for moderate to severe TBI includes: medicines for pain, psychiatric 
medications, such as antidepressants, and psychotherapy (DiTommaso, Hoffman et al. 2014; 
Dobry, Novakovic et al. 2014). This treatment is based off those TBI patients who also present 
conditions such as post-concussive syndrome (PCS) and posttraumatic stress disorder 
(PTSD).According to the reports by the Eunice Kennedy Shriver National Institute of Child 
Health and Human Development (NICHD), approximately 40% of all TBI patients develop PCS. 
This syndrome is more common among people who have a pre-existing psychiatric problem, 
such as depression or anxiety, before suffering a TBI (NINDS, 2012). The Substance Abuse 
and Mental Health Services Administration in 2010 reports as complications: motor deficits, 
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cognitive disabilities and mood disorders, such as anxiety, depression, and post-traumatic 
stress disorder.  
There is no effective therapy available that can cure TBI due to the complex cascade of 
secondary events that lead to multiple sequelae. Yet, among the secondary injury mechanisms, 
there is one which may not in itself detrimental: inflammation.  It is a “necessary evil” by which 
the body tries to regain equilibrium. Studies supporting this healing vision describe  
inflammation, in most cases, as a well coordinated set of connections operating at an 
intermediate time scale between neural and longer-term endocrine processes (Vodovotz, Csete 
et al. 2008); and necessary for the removal of challenges to the organism and subsequent 
restoration of homeostasis (Nathan 2002; Kadl and Leitinger 2005; Pate, Damarla et al. 2010).  
Nonetheless, inflammation in many disease conditions is described as a double-edged sword 
(Cole 1986; Smith 1994; Hagemann, Balkwill et al. 2007; Doyle and Buckwalter 2012; 
Cerecedo-Lopez, Kim-Lee et al. 2014). In plain words, if inflammation had a zodiac sign it would 
be a “Gemini”, Gemini are a mix of the yin and the yang, love and hate, peace and war, etc. 
Inflammation in the brain can exert detrimental and healing effects.  The inherent function of 
inflammation is to recruit various immune cell types into the site of the injury to remove 
damaged tissue and cellular debris allowing further creation of scar tissue (Cerecedo-Lopez, 
Kim-Lee et al. 2014). The main surveillance immune cell responsible for responding to an injury 
within the central nervous system (CNS) is microglia. Microglia activation shows three 
profiles/phenotypes depending on the stimuli: classical activation, alternative activation, and 
acquired deactivation. Classical activation is associated with pro-inflammatory mechanisms, 
whereas the other two are promoters of anti-inflammatory mechanisms (Luo and Chen 2012). 
The ambivalent property of inflammation is what makes it more valuable over other secondary 
cell death events which do not have a two way street to reverse and shift from damage to repair. 
The pathological consequences of TBI cannot be encompassed by the available 
pharmacological, cognitive, and behavioral diagnostic tools. These tools are deficient because 
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of the broad range of TBI conditions with divergent cell death mechanisms. In order to improve 
care of patients with TBI we suggest the identification of inflammatory markers that shift and 
promote inflammation towards repair, keeping in mind age and gender differences. For 
example, in cell and animal models of cerebral ischemia, therapies designed to down regulate 
inflammatory pathways are more effective in male models compared to female models (Chen, 
Toung et al. 2005; Bushnell, Hurn et al. 2006). Therefore, it is relevant to keep in mind 
preclinical and clinical research to help explain age and gender differences in disease to 
optimize diagnosis, treatment and a favorable clinical outcome. Altogether, these findings 
suggest the identification of novel inflammatory markers that promote inflammation towards 
repair, taking into consideration important variables, such as age and gender that can impact 
clinical outcomes. 
Intense research in the past decade suggests that TBI is associated with conditions that 
cause the breakdown of brain cells, such as Alzheimer’s disease (AD), Parkinson’s Disease 
(PD),  and chronic traumatic encephalopathy (Abisambra and Scheff 2014; Chauhan 2014; 
Lucke-Wold, Turner et al. 2014). These neurodegenerative diseases have a strong 
neuroinflammatory component.  And interestingly enough, complications such as chronic 
neuroinflammation and neurodegeneration have also been associated to TBI (Viscomi and 
Molinari 2014). Thus, these neuroinflammatory and degenerative components link TBI to certain 
neurodegenerative disorders. Further understanding of this neuroinflammatory process and cell 
death pathways in TBI could explain neurodegeneration in AD and PD patients. In parallel, a 
similar inflammatory and cell injury pathway in a neurodegenerative disease may also become 
activated in TBI patients.  Overall, studying the neuroinflammatory process is likely to elucidate 
pathological mechanisms associated with the disease, as well as provide novel pathways in 
treating TBI and related neurodegenerative disorders.  
In addition to conventional TBI treatment and standard rehabilitation, novel therapeutic 
approaches have been introduced to promote cell survival and arrest TBI-induced cell death. 
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Proposed therapies attempt to reduce inflammation, promote neuronal survival, and rescue 
injured neurons from cell death.   example,, studies in acute spinal cord injury (SCI) in humans 
and rodents have shown overlapping cytokine profiles, interleukin 6 (IL-6), interleukin 8  (IL-8), 
and  monocyte chemoattractant protein 1(MCP-1),  released in an SCI injury dependent manner 
(Stammers, Liu et al. 2012) suggesting these molecules as potential targets to  attenuate 
microglia activation and inflammation. In addition, experiments in TBI human and rodent models 
coincide in cytokine profiles for: interleukin 1β (IL-1β) detection in human CSF; IL-6, and 
interleukin 10 (IL-10) detection in plasma and serum of humans and rodents (Bell, Kochanek et 
al. 1997; Kamm, Vanderkolk et al. 2006; Woodcock and Morganti-Kossmann 2013; Yan, 
Satgunaseelan et al. 2014).Furthermore, other novel drug therapies attempt tackle oxidative 
stress, a mechanism of secondary brain injury. This approach suggests the use of agents such 
as mitochondria-targeted antioxidants (melatonin and new mitochondria-targeted antioxidants), 
nicotinamide adenine dinucleotide phosphate (NADPH) inhibitors (antioxidant vitamins and 
apocynin), and other compounds having mainly antioxidant properties (hydrogen-rich saline, 
sulforaphane, U-83836E, omega-3, and polyphenols) (Fernandez-Gajardo, Matamala et al. 
2014). These different compounds have shown positive and promising results in rodent TBI 
models.  Melatonin  at appropriate doses reduced the amount of lesion volume, the loss of 
motor function,  the expression of pro-apoptotic proteins, inducible nitric oxide synthase  (iNOS), 
and matrix metalloproteinases (MMPs) (Campolo, Ahmad et al. 2013). One example is 
mitochondria-targeted antioxidants: (i) plastoquinone derivatives, and  (ii) ubiquinone derivatives 
at high doses showed: (i) a reduction in reactive oxygen species (ROS), and cortical lesion 
volume (Liberman, Topaly et al. 1969; Antonenko, Avetisyan et al. 2008); (ii) and  
neuroprotective effects (James, Cocheme et al. 2005; Murphy and Smith 2007)). Other 
alternative agents showing neuroprotective effects in TBI rat models were the intravenous 
administration of vitamin C (Polidori, Mecocci et al. 2001; Riordan, Riordan et al. 2004), and 
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dietary supplementation of vitamin E treatment in TBI rat models (Aiguo, Zhe et al. 2010; Yang, 
Han et al. 2013), and in patients with severe TBI (Razmkon, Sadidi et al. 2011). 
Overall, the pharmacological therapies are partially effective; they seem to reduce pro 
inflammatory cytokines, promote neuroprotection, and slight functional recovery, but their level 
of efficacy has not improved dramatically the quality of life in a patient’s road to recovery.  The 
challenge that TBI drug therapy faces is to facilitate these agents to cross the BBB to treat 
patients quickly in the ER, and in the clinic. The pharmacokinetics and pharmacodynamics of 
the drug and their method of delivery are also factors that should be taken into consideration. 
Thus, to gain definitive insight of: (i) the pharmacokinetics and pharmacodynamics of a 
drug/agent, (ii) its capacity  to penetrate the BBB, (iii) and any delivery parameters; scientists 
could pursue a collaborative effort/project that compiles/encompasses above features in unison 
with help of genomics, proteomics and metabolomics to identify “ideal therapeutic 
biomarkers/drugs. This study considers a pharmacologic approach in understanding TBI 
pathology and treatment, by using an inhibitory drug that will exert an anti-inflammatory effect. 
Using an in-vitro cell model we will attempt an upstream inhibitory approach to block the 
suggested inflammatory biomarker and observe its effects in the cells. 
In the last 4 years two novel therapeutic agents were introduced into human clinical trials 
for their potential efficacy in TBI: progesterone and glyburide. The first agent is progesterone. 
The hypothesis that progesterone has neuroprotective effects was introduced  nearly 25 years 
ago in a rat model of TBI (Roof, Hoffman et al. 1997).  Next, a small pilot human TBI study 
followed to assess progesterone’s safety, which showed neuroprotective effects as seen in 
animal studies (Wright, Bauer et al. 2001; Pettus, Wright et al. 2005; Stein and Wright 2010). 
The endogenous properties of progesterone made it an optimal therapeutic TBI candidate. 
Progesterone is present in the brain already, besides being a hormone that supports pregnancy; 
it plays a role in brain development in men (Wagner 2006) and women (Wright, Kellermann et 
al. 2007); it has no problems crossing the BBB due to its steroidal nature and regenerative 
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properties (He, Hoffman et al. 2004; Bali, Arimoto et al. 2012; Sitruk-Ware and El-Etr 2013). 
Perhaps the most notorious feature of progesterone is its rapid mechanism of action to exert 
anti-inflammatory, neuroprotective and regenerative effects in the CNS, and systemically, 
creating a therapeutic window to treat patients.  Recent human Phase III clinical trial, Protect, 
seems very promising to elucidate progesterone’s efficacy when administered within hours of 
brain injury to protect neurons and tissues from secondary damage mechanisms.   
The second therapeutic agent in an undergoing clinical trial is the intravenous form (IV) 
of glyburide (RP-1127). Glyburide or glibenclamide is an inhibitor of sulfonyl urea receptor 
1(SUR-1) widely used to treat type 2 diabetes (Quast, Stephan et al. 2004) . SUR are molecular 
targets of antidiabetic drugs which act to promote insulin release from the pancreatic beta cells.  
Another interesting feature of glyburide is that it has anti-inflammatory effects (Koh, Maude et al. 
2011). Therefore, the clinical trial should focus on ADMET parameters (as noted below) of the 
therapeutic agent, safety and efficacy of the drug after TBI, and on identifying what inflammatory 
trades decrease after swelling and bleeding in brain.  Thus, we intend to study the features of a 
novel biomarker with a potential inflammatory role in TBI. We are interested in finding traits that: 
(i) suggest inflammation and a therapeutic window of the biomarker after mild TBI; (ii) address a 
particular therapeutic agent that could penetrate the BBB and influence the biomarker’s activity; 
and (iii) note if the therapeutic agent has any notorious absorption, distribution, metabolism, 
excretion, toxicity (ADMET) parameters.  Thus, with the proposed pharmacologic approach in 
characterizing the TBI-induced neuroinflammation, this study would be able to gain insights on 
potential inflammatory biomarkers, as well as begin to understand putative therapeutic agents 
(as discussed below) which may influence the neuroinflammatory response towards brain 
repair.   
A third therapeutic platform is the use of cytokines/chemokines alone or in combination 
with stem cell therapy to channel the migration of stem cells to the brain. These chemotactic 
approaches propose the use of neurotrophic factors to treat CNS diseases (Liu, Fawcett et al. 
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2001; Thorne and Frey 2001) and as guidance for stem cells from the periphery to the site of 
brain injury, thereby allowing efficient brain bioavailability of the grafted cells’ secreted 
therapeutic molecules (Borlongan 2011; Borlongan, Glover et al. 2011). Such inflammation-
mediated cell migration suggest that a modest cytokine/chemokine upregulation aids stem cells 
in reaching their brain injured target areas (Hernandez-Ontiveros, Tajiri et al. 2013). Scientists 
and clinicians should keep in mind the adverse effects of disturbing the delicate equilibrium 
between pro-inflammatory and anti-inflammatory cytokines in microglial function.  
Accumulating evidence has demonstrated the potential of stem cell therapy to treat TBI 
and other neurodegenerative conditions. The principle behind this is to utilize the proliferative 
capacity of stem cells for the appropriate neurological condition. Transplanted stem cells appear 
to work by direct cell replacement and by neurotrophic effects, resulting in  immunomodulation 
and upregulation of endogenous stem cells (Sanberg, Eve et al. 2012).  Yet, a contingency plan 
should exist to determine the suitable cell type, whether to perform allogeneic or autologous 
transplants based on the neurological disorder, and the level of stimulation of the host’s immune 
system to the graft. Autologous stem cell transplants are preferable over allogeneic ones 
because they have minimum risk of graft rejection since they are from the same patient from 
which they were initially taken. In contrast, allogeneic transplants occur when the stem cells 
come from another donor with closely matched immune markers, but the recipient’s immune 
system may still cause an abrupt reaction with immediate rejection, severe consequences and 
possibly death.  Studies in the stem cell field support the two schools of thought in stem cell 
repair:  (i) direct cell replacement by exogenous stem cells into the damaged region of the brain, 
and (ii) trophic factor stimulation of endogenous stem cells within neurogenic niches or recruited 
from the bone marrow through peripheral circulation (Borlongan, Glover et al. 2011; Shinozuka, 
Dailey et al. 2013). It is very likely that injected stem cells are able to migrate from the 
bloodstream to the brain because the injured brain sends out chemical signals that recruit stem 
cells. Additionally, stem cells have an easier way coming in since the injured brain has a 
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compromised BBB. A third mechanism of action proposes a regenerative long-distance 
migration of host cells from the neurogenic niche to the injured brain site can be achieved 
through transplanted stem cells serving as “bio-bridges” for initiation of endogenous repair 
mechanisms (Tajiri, Kaneko et al. 2013). All three mechanisms have a promising future, as they 
could be translated in the clinical arena to treat patients who have suffered from TBI and other 
neurodegenerative diseases.  
Stem cell therapy needs optimization in the clinic. Due to the safety issues associated 
with transplanting stem cells, testing donors and recipients to ascertain immune incompatibility, 
will require quality assurance and control in handling, storing, and performing the surgical 
techniques for the delivery of stem cells to minimize any mortality and morbidity risks.  Equally 
challenging in advancing novel therapies to the clinic include reproducibility of safe and effective 
outcomes that will lead to robust and stable functional recovery in transplanted TBI patients.  To 
this end, there is a need to achieve prompt approval, regulatory guidelines, and accreditation by 
the Food and Drug Administration (FDA) and existing health entities. Both of the proposed anti-
inflammatory and stem cell therapies aim to rescue dying neurons, ameliorate secondary injury 
mechanisms, which translate to alleviate the symptoms and improve the quality of life of TBI 
patients. We envision that our proposed anti-inflammatory agent will be screen on blood or 
plasma of TBI patients arriving to the ER, and based on the described therapeutic window, treat 
patients with therapeutic agents that abrogate neuroinflammation.  Both therapeutic approaches 
can be combined to potentiate synergistic effects that could decrease extent of the inflammatory 
signaling pathways activated during TBI.  A recent study proposes to stimulate and mobilize 
endogenous stem/progenitor cells from the bone marrow in combination with an anti-
inflammatory agent granulocyte colony stimulating factor (G-CSF) (Acosta, Tajiri et al. 2014). 
This team found out that transplanted stem cells influence the endogenous stem cells by 
secreting neurotrophic factors, anti-inflammatory cytokines, overall regulating the milieu 
associated with chronic neuroinflammation found in TBI. It appears that combinational therapy 
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of grafted stem cells with anti-inflammatory agents will be a more viable tool than monotherapy 
of anti-inflammatory agents alone. Based on above study, in order to see improved behavioral 
outcome it is necessary: (i) a successful grafted stem cells integration into the recipient brain 
tissue; (ii) induction of an endogenous repair mechanism in the host; and (iii) a collaborative 
brain repair process mutually solicited by grafted stem cells and endogenous ones. 
 
1.1.1 Societal Burden Costs 
The high rates of mild traumatic brain injury and posttraumatic stress disorder in current 
operations are of significant concern for the long-term health of US veterans with associated 
economic implications. From the estimated 1.7 million people who sustain a TBI in a year, 
personal and social costs associated with TBI are between 9 and 10 billion dollars annually 
(NIH, 1999). According to NINDS, total TBI costs in the USA exceed $56 billion a year. Thus, 
development and testing of novel therapeutics and devices in the short and long term is a 
priority to treat patients and help them regain functional recovery and rehabilitation. One factor 
to keep into consideration is the therapeutic window to treat a patient with TBI.  Using the 
concept of combined therapy we increase our chances of finding an adequate drug therapy to 
reduce excessive annual costs associated with TBI. We can also reduce healthcare and 
hospitalization costs by educational campaigns for the prevention of TBI injuries among seniors, 
soldiers and children. Advances in protective gear may also lower the risk for TBI. As more 
sensitive and practical biomarkers are introduced in the clinical setting, it is likely that the 
societal costs and burden for TBI will be minimized. To this end, this study desired to advance 
our basic science knowledge in testing a potential biomarker for TBI. 
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1.1.2 Gaps in Basic Science Knowledge of TBI  
TBI is a multifaceted condition, not a single event. Current therapeutic strategies attempt 
to limit primary and secondary brain damage that occurs within days of a head trauma. It is 
difficult to stop the progression of neuronal loss and the cascade of secondary cell death events 
after TBI. Countless years of research and experience have shown, almost in all CNS 
pathologies, it is very unlikely that a single therapy may protect from degeneration (Viscomi and 
Molinari 2014). Among the various secondary injury mechanisms, we found neuroinflammation. 
Multiple studies suggest that neuroinflammation, in the form of microglial activation, is a 
mechanism underlying chronic neurodegenerative processes after traumatic brain injury (Smith, 
Gentleman et al. 2013). Our study focuses in identifying any inflammatory alterations associated 
with CD-36 in TBI. The gap in basic science knowledge is the lack of understanding of the 
neuroinflammatory process in TBI. There are numerous inflammatory signaling pathways that 
we do not understand. One of these inflammatory signaling pathways may involve CD-36.  This 
biomarker has been proposed as a mediator of inflammation in certain metabolic and 
degenerative disorders, such as hypercholesterolemia, atherosclerosis, stroke, AD, PD, and 
dementia pugilistica. We hypothesize that CD-36 plays an inflammatory role in TBI pathology. 
This study hopes to reduce the gap in knowledge of the neuroinflammatory process with other 
molecular processes in TBI. We expect to reduce the gap in knowledge by addressing any 
temporal profile of CD-36 activation/expression in acute and chronic stages of TBI. In addition, 
we may have found a therapeutic window to test a pharmacological agent suitable for inhibiting 
CD-36.  Yet, we recognize that different strategies have to be explored and combined to target 
neuroinflammation but other secondary mechanisms of damage after TBI.  
 
1.1.3 Gaps in Translational and Clinical Knowledge in TBI  
Despite the knowledge we have in the pathological mechanisms of TBI, current 
advances in medicine has failed to translate into a single successful clinical trial treatment that 
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addresses all the complications that TBI patients face. Part of the challenge may be attributable 
to the broad classification of TBI as mild, moderate and severe. In addition, there is also a 
translational gap in the range of doses (concentrations) of a drug that elicits a therapeutic 
response, known as therapeutic window.  Diagnostic tools, such as imaging and proteomic 
biomarkers are not as useful without defining a therapeutic window to treat TBI patients. 
Delineating the therapeutic window for acute and chronic stages of TBI will reduce the number 
of misdiagnosed TBI patients in the ER; capture more TBI patients, and provide with more 
specific or elaborate tests that provide accurate cognitive and motor assessment in TBI patients. 
At the same time, we are trying to identify novel biomarkers as therapeutic targets after brain 
injury in acute and chronic TBI stages. Our novel biomarker may serve as an indicator of short 
and, or prolonged stages of inflammation after TBI.  In addition, the proposed novel biomarker 
may be feasible for screening patients in the ER room immediately after TBI, or later after injury, 
and it could serve as a prognosis and diagnostic tool in a patient’s rehabilitation process. The 
translation gap in knowledge of TBI is a deficiency in diagnosis, especially when severity is mild 
or moderate, as in the case of concussion or slight head trauma. 
In the clinical arena, there are many novel and promising therapeutic agents which have 
failed to demonstrate they can promote functional and neuroprotective effects. More evidence 
needs to be compiled to assess its efficacy; whether in animal, and/or human TBI clinical trials.  
Despite exciting pre-clinical results, more than 30 phase III prospective clinical trials have failed 
to display significance for their primary outcome (Narayan, Michel et al. 2002; Schouten 2007; 
Maas, Roozenbeek et al. 2010). Results from pre-clinical trials have not been translated into 
successful clinical trials due to: (i) the pathophysiological heterogeneity of TBI patients, (ii) lack 
of sufficient pharmacokinetic analysis for determination of optimal dose, (iii) and therapeutic 
window of the target compounds. The general challenge we face, one that is addressed in this 
study, is to find a novel therapeutic agent that favorably shifts the inflammatory response from 
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damage to repair, thereby promoting neuronal survival and functional recovery in TBI within 
clinical relevant parameters.   
Finally, a gap in knowledge that also needs attention is the methodology differences 
between animal, pre-clinical, and clinical studies. A great procedural disparity exists when 
transitioning from animals to humans. Procedural factors such as (i) the influence of anesthetic 
drugs (used in TBI models) on the primary outcomes of the study, (ii) potential drug/anesthetic 
interactions (Statler, Alexander et al. 2006), (iii) methodological analysis of results, (iv) the use 
of genetically identical populations in TBI models, and (v) the time course of pathophysiological 
and therapeutic effects, among others (Fernandez-Gajardo, Matamala et al. 2014). In this study 
we hope to provide evidence that serves to establish a time course profile of our novel 
biomarker that helps establish a therapeutic window to treat TBI.  Here you are alluding to a 
likely disconnect between the basic science and the clinic and that animal modeling of TBI 
needs to closely mimic the disease.  You need to clearly state this gap. Current animal models 
of TBI cannot identically replicate the human TBI model due to certain procedural factors. 
Nevertheless, the CCI model is chosen mainly because it produces: (i) a pronounced cortical 
contusion, (ii) morphological and cerebrovascular injury responses that resemble various 
aspects (e.g. edema, inflammation, BBB disruption) of human TBI, and (iii) neurobehavioral and 
cognitive impairments  like those seen in human patients (Dixon and Kline 2009).  
 
1.2 Cell Death Mechanisms Associated with Secondary Damage in TBI 
This section will cover secondary mechanisms of injury: edema, inflammation, neuron 
excitotoxicity, mitochondrial dysfunction, apoptosis and necrosis. Current animal models of TBI 
include a biomechanical procedure known as controlled cortical impact (CCI) (LaPlaca, Simon 
et al. 2007; Tehranian, Rose et al. 2008). These techniques are employed in an attempt to 
reproduce some of the pathology present in human TBI. For example, in the CCI model animals 
endure an initial necrotic process in the cortical tissue and white matter axonal injury, followed 
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by apoptosis in surrounding tissue due to secondary events such as edema, ischemia, 
excitotoxicity,  altered gene expression, and other pathways depicted below (Figure 1). (Park, 
Bell et al. 2008; Hayashi, Kaneko et al. 2009; Boone, Sell et al. 2012; Johnson, Stewart et al. 
2012; Rovegno, Soto et al. 2012). 
Figure 1 below depicts the complexity of the “secondary injury” mechanisms that 
exacerbate the initial injury. These molecular pathways may act in parallel , and or interact  
among them (Park, Bell et al. 2008). This chaotic scenario leaves us with a very narrow window 
of opportunity to react. Once the immune system engages in this chaotic environment, it mounts 
very abrupt microglial activation, recruiting surveillance monocytes; and other immune cells from 
the periphery to the site of injury. Focal damage is typically seen around hemorrhagic lesions, 
such as contusions within the gray matter or at gray-white junctions (Richardson, Singh et al. 
2010); at the frontal and temporal poles and in the orbital frontal cortex (Gennarelli and Graham 
1998). White matter—the part of the brain that provides long connections between different 
parts of the grey matter or cortex—exhibits different patterns of deterioration compared with 
grey matter (Park, Bell et al. 2008). Traumatic axonal injury is a common occurrence in both 
focal and diffuse brain trauma regardless of injury severity (Cordobes, Lobato et al. 1986; 
Gentleman, Roberts et al. 1995). Equally compelling evidence suggests that following the acute 
phase of focal TBI and brain ischemic events, hippocampal neurons may be the most 
vulnerable neurons in the brain, as they show the earliest evidence of neurodegeneration in 
experimental models (McIntosh, Saatman et al. 1998) with the dentate gyrus displaying reduced 
neurogenesis (Acosta, Tajiri et al. 2013) coinciding with profound memory impairment in both 
human and animal models of TBI (Smith, Okiyama et al. 1991; Umile, Sandel et al. 2002). The 
sequence of secondary cell death events is very complex and hard to follow due to the 
numerous signaling pathways associated with inflammation and cell death.   
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Figure 1. Mechanisms associated with secondary damage in TBI. The major pathways 
associated with the progression of secondary injury after a traumatic brain injury: M 
icrocirculatory derangements involve stenosis (1) and loss of microvasculature, and the blood–
brain barrier may break down as a result of astrocyte foot processes swelling (2). Proliferation of 
astrocytes (“astrogliosis”) (3) is a characteristic of injuries to the central nervous system, and 
their dysfunction results in a reversal of glutamate uptake (4) and neuronal depolarization 
through excitotoxic mechanisms. In injuries to white and grey matter, calcium influx (5) is a key 
initiating event in a molecular cascades resulting in delayed cell death or dysfunction as well as 
delayed axonal disconnection. In neurons, calcium and zinc influx though channels in the AMPA 
and NMDAreceptors results in excitotoxicity (6), generation of free radicals, mitochondrial 
dysfunction and postsynaptic receptor modifications. These mechanisms are not ubiquitous in 
the traumatized brain but are dependent on the sub-cellular routes of calcium influx and the 
degree of injury. Calcium influx into axons (7) initiates a series of protein degradation cascades 
that result in axonal disconnection (8).Inflammatory cells also mediate secondary injury, through 
the release of pro-inflammatory cytokines (9) that contribute to the activation of cell-death 
cascades or postsynaptic receptor modifications (Park, Bell et al. 2008). Reprinted from (E. 
Park, J. D. Bell, A. J., Baker) (Traumatic Brain Injury can the consequences be stopped?, Figure 
1.The major pathways associated with the progression of secondary injury after a traumatic 
brain injury) Canadian Medical Association Journal (April 22 2008, Volume 178 No. 9, pages 
1163–1170). © Canadian Medical Association (2008). This work is protected by copyright and 
the making of this copy was with the permission of the Canadian Medical Association Journal 
(www.cmaj.ca) and Access Copyright. Any alteration of its content or further copying in any form 
whatsoever is strictly prohibited unless otherwise permitted by law. 
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Is the basic science able to capture these secondary cell death mechanisms? Basic 
science is not able to grass all the elements of the puzzle in secondary cell death events. The 
two mechanisms that occur in TBI are necrosis, happening immediately after injury; and 
neuronal cell death occurring in a delayed fashion. Both mechanisms have been documented in 
ischemia, and TBI (Liou, Clark et al. 2003; Zhang, Chen et al. 2005). Since apoptosis is a 
programmed cell death process, it is a much better candidate to target for therapeutic 
approaches. Experimental studies point at two promising pharmacological agents: caspase 
inhibitors to target caspase dependent apoptosis and poly ADP-ribose polymerase (PARP) 
inhibitors to target caspase independent cell death (Zhang, Chen et al. 2005).Yet, the gap of 
knowledge remains at which step in the apoptotic pathway is convenient to intervene, and a 
convenient  therapeutic window. Because activation of these pathways occurs in parallel and 
peaks 1–3 days after injury, such strategies should be:  both additive and synergistic; and 
should show a relatively wide therapeutic window (Stoica and Faden 2010). Currently, there are 
NIH clinical and translational experiments testing anti-apoptotic agents in cancer, but not in TBI 
patients. Interestingly enough, a safe anti-apoptotic agent could be developed that enables us to 
test its effects in TBI. For example, the selective inhibitors of nuclear export (SINE) compounds 
that inhibit the function of the nuclear export protein exportin 1(XPO1) have the potential to 
provide a novel targeted therapy that enable tumor suppressor proteins to remain in the nucleus 
and promote apoptosis of cancer cells (Cheng, Holloway et al. 2014; London, Bernabe et al. 
2014). The company Karyopharm has discovered XPO1-inhibiting SINE compounds, including 
Selinexor and they believe that SINE compounds may have the potential to provide therapeutic 
benefit in various cancers, autoimmune and inflammatory diseases, wound healing, HIV, and 
influenza (Karyopharm, 2014). With respect to necrosis, little can be done to stop it, since the 
sole impact of brain injury causes neuronal damage and death within minutes; yet those 
neurons in the vicinity of injury can still be rescued pharmacologically or with stem cell therapy. 
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 More investigations are necessary to further document necrosis and any key molecules 
within the apoptotic cascade as potential therapeutic targets to treat TBI.  
1.2.1 Neuroinflammation 
This section will focus on reviewing the inflammatory response associated with CD-36 in 
an effort to characterize the pathological cascade and therapeutic window associated with this 
inflammatory pathway. In the past decade studies have focused attention on neuroinflammation 
in the form of microglial activation, as a mechanism of potential relevance to neurodegeneration 
both in AD and in the response to brain injury (Griffin, Sheng et al. 1998; Gentleman, Leclercq 
et al. 2004). Emerging evidence suggests that neuroinflammation and microglial activation in the 
white matter may also contribute to ongoing cellular damage (Loane and Byrnes 2010), and it 
may persist for years after injury in humans (Gentleman, Leclercq et al. 2004; Chen, Johnson et 
al. 2009). After brain injury cytokines are released activating microglia, the degree of activation 
reflecting the severity of the injury (Igarashi, Potts et al. 2007; Smith, Gentleman et al. 2013). 
Microglial activation will lead to further cytokine release, including interleukin (IL)-1, possibly 
secondary to elevated levels of adenosine-5′-triphosphate (ATP) released from damaged cells 
(Di Virgilio 1995), with activation of purinergic P2X7 receptors on microglia (Ferrari, Chiozzi et 
al. 1997). IL-1 is expressed in increased quantities in the cerebral cortex within hours of TBI 
(Griffin, Sheng et al. 1994; Smith, Gentleman et al. 2013). Griffin et al., 1998 have proposed a 
“cytokine cycle” in which traumatic brain injury, or other forms of brain injury, can, in susceptible 
individuals, initiate an over-exuberant sustained inflammatory response that can result in 
neurodegeneration (Griffin, Sheng et al. 1998). 
The inflammatory response after TBI results in neuronal injury and disruption of the 
blood-brain barrier (Smith DH 1997; Nagamoto-Combs, McNeal et al. 2007; Namas, Ghuma et 
al. 2009). Microglial cells quickly become activated, they act as antigen presenting cells (APCs) 
releasing pro-inflammatory cytokines and chemokines (Town, Nikolic et al. 2005; Cao, Thomas 
et al. 2012). Activated microglia also produces nitric oxide (NO) and superoxide free radicals 
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that generate reactive oxygen species (ROS) and reactive nitrogen species (RNS). In animal 
models of cortical controlled impact (CCI); fluid-percussion brain injury in rats; combined 
unilateral lesion of the primary motor cortex and of the lateral pre-motor cortex in rhesus 
monkeys, microglial cells remain in their activated state for at least one year, especially in the 
thalamic area (Smith DH 1997; Nagamoto-Combs, McNeal et al. 2007; Nagamoto-Combs and 
Combs 2010; Jacobowitz, Cole et al. 2012; Jin, Ishii et al. 2012). Recent experiments with 
human postmortem tissue showed microglial activation 17 years after TBI in sub-cortical brain 
areas (Ramlackhansingh, Brooks et al. 2011). These accrued reports suggest a chronic 
inflammatory stage sustained by microglia.  
A recent study by Smith et al., 2013 reinforces the hypothesis that the microglial 
response to head injury may persist and provoke chronic neurodegeneration in humans. The 
team depicted the time-course and magnitude of the microglial reaction in human post mortem 
cases. Their major finding was a neuroinflammatory response developing within the first week 
and persisting for several months after TBI, but has returned to control levels after several years 
(Smith, Gentleman et al. 2013). In addition, they also examined cases with diffuse traumatic 
axonal injury and found that microglial reaction is particularly pronounced in the white matter. 
Altogether, the current literature reinforces the thought  that prolonged microglial activation is a 
hallmark of traumatic brain injury, but may also suggests that  neuroinflammatory response 
returns to control levels after several years based on the severity of the injury. The proposed 
study will address any CD-36 related inflammatory alterations in an animal model of TBI at 
acute and chronic stages. We will gain insight in the expression patterns of CD-36 in the brain 
and spleen, which will support our hypothesis that CD-36 has a pivotal role in the 
neuroinflammatory cascade at early stages, and possibly in chronic stages of TBI-related 
inflammation. Exploiting this CD-36 mechanism as a candidate therapeutic target may abrogate 
secondary cell death in TBI and promote functional and cognitive brain recovery.  
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A role for CD-36 has been implicated in the pathogenesis of various diseases. However, 
its role in traumatic brain injury (TBI) has not been examined. According to the National Health 
and Nutrition Examination Surveys approximately 70% of adults are overweight or obese; 
roughly 78 million adult Americans are considered obese (NHANES, 2009-2010). Interestingly, 
CD-36 has recently being associated with inflammatory events in lipid metabolic disorders,  
atherosclerotic plaque formation, and cerebral ischemia, TBI pathology, and Alzheimer’s 
disease (Coraci, Husemann et al. 2002; Kunjathoor, Febbraio et al. 2002; Cho, Szeto et al. 
2007; Kim, Febbraio et al. 2012; Pietka, Schappe et al. 2014). CD-36 shows high affinity toward 
lipid-based ligands such as oxLDL, or mLDL and long chain-fatty acids among other ligands, 
including thrombospondins, fibrillar β-amyloid, and membranes of cells undergoing apoptosis 
(Martin et al., 2011; Abumrad et al., 1993; Savill, 1997; Febbraio et al., 2001; Medeiros et al., 
2004). Although the effect of CD-36 on atherogenesis is debatable (Moore et al., 2005; Moore 
and Freeman, 2006), uptake of pro-inflammatory oxLDL or mLDL by macrophage CD-36 is a 
critical step that leads to foam cell formation, atheroma, and a chronic pro-inflammatory state 
(Febbraio et al., 2000; Podrez et al., 2002a,b; Rahaman et al., 2006; Guy et al., 2007). 
The signaling pathways of CD-36 are not fully understood, yet research strongly 
suggests it has a key inflammatory role in cardiovascular conditions. In the case of 
atherosclerotic lesions CD-36 is expressed by phagocytes and vascular cells, likely candidates 
to mediate the in vivo oxidation of LDL and the maintenance of the inflammatory process 
(Marsche, Zimmermann et al. 2003; Greaves and Gordon 2009; Kannan, Sundaram et al. 
2012). For instance LDL-HOCl induces chemokines release of monocytes and chemotactic 
migration of neutrophils (Woenckhaus, Kaufmann et al. 1998),  initiates the respiratory burst of  
macrophages and stimulates polymorphonuclear leukocytes to an enhanced production of 
superoxide anion radical and hydrogen peroxide (Nguyen-Khoa, Massy et al. 1999). 
CD-36 is expressed by macrophages in the brain and periphery, playing a big role in the 
inflammatory response. This scavenger receptor, internalizes cholesterol-laden modified 
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lipoproteins. Uncontrolled cholesterol accumulation in macrophages may result as an adaptive 
mechanism in response to excessive lipid load and lead to foam cell formation (Febbraio, Guy 
et al. 2004). These foam cell formation is part of the initial lesion in atherosclerosis, known as 
fatty streak (Lusis 2000). Oxidative modification of low-density lipoprotein (LDL) has been 
hypothesized to be a key event in the conversion of LDL to a pro-atherogenic form recognized 
by macrophage scavenger receptors (Steinberg 1997; Kunjathoor, Febbraio et al. 2002). Thus, 
internalization of oxidized LDL (oxLDL) by macrophages is an early and potentially pivotal event 
which, if inhibited through intervention at the level of the scavenger receptor, may delay the 
atherosclerotic process.  
Furthermore, in an atherosclerotic model with chimeric mice lacking CD-36 
macrophages, stem cell transplantation revealed that absence of macrophage CD-36 was 
protective against atherosclerosis. These mice lacking CD-36 were protected against 
atherosclerosis, they had  88.1% reduction of lesion area throughout the aortic tree (Febbraio, 
Guy et al. 2004). Thus, our interest in CD-36 lies in the characterization of any inflammatory 
alterations in an adult animal model of CCI. In controlled cortical injury models, selective 
neuronal death has been well described in the hippocampus (Morales, Marklund et al. 2005);  
but a diffuse axonal injury animal model showed that despite the proximity of traumatic axonal 
injury to the neuronal somata, neuronal cell bodies do not show a pathological progression to 
cell death, and in fact exhibit changes suggestive of reorganization and potential repair 
(Singleton, Zhu et al. 2002).  
In this study we would like to: (i) identify what brain regions express CD-36; (ii) label and 
identify what cells are expressing CD-36, and which glial cells are associated with CD-36 in the 
inflammatory response at the acute and chronic TBI stages. Spleen has an important role after 
CNS injury, spleen is a big reservoir of macrophages that play a big role in the immune 
response after stroke and brain injury (Rasouli, Lekhraj et al. 2011; Seifert, Hall et al. 2012; 
Seifert, Leonardo et al. 2012; Schwulst, Trahanas et al. 2013). We are also interested in finding 
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any time-dependent CD-36 expression patterns in both organs after TBI.  We are concerned 
with identifying what brain regions are mainly associated with CD-36 expression. We expect that 
this project of CD-36 helps elucidate its inflammatory process after TBI; any time dependent 
CD-36 expression/activation will contribute in building up a therapeutic window to treat acute 
and chronic TBI stages; it will serve as basis to design more experimental studies that can be 
translated to pre-clinical studies that consider CD-36 as a potential therapeutic target to reduce 
neuroinflammation in TBI and other disorders. 
  
1.3 CD-36, Fatty Acid Translocase 
We will define CD-36, the main functions of this molecule, and inflammatory links to lipid 
metabolic disorders, and degenerative diseases. CD-36 is referred to as a type B scavenger 
receptor. It is a member of a family of receptors which also includes SR-B1/CLA-1, a high 
density lipoprotein receptor. Medgen reports CD-36 is expressed by monocyte/macrophages, 
platelets, microvascular endothelial cells, and adipose tissues. CD-36 recognizes a broad 
variety of ligands including oxLDL, anionic phospholipids, apoptotic cells, thrombospondin 
(TSP), collagen, Plasmodium Falciparum-infected erythrocytes, and long-chain fatty acids. 
Scavenger receptors are known to be involved in: innate immune responses (Peiser and 
Gordon 2001; Kennedy, Chen et al. 2012), cell adhesion (Avril, Tripathi et al. 2012) , 
phagocytosis of apoptotic cells (Ren, Silverstein et al. 1995; Leelahavanichkul, Bocharov et al. 
2012), and lipid uptake (Mitchell, On et al. 2011; Moulle, Cansell et al. 2012). 
Other relevant functions of CD-36: serve as a receptor for thrombospondin in platelets 
and various cell lines. It binds to collagen, thrombospondin, anionic phospholipids and oxLDL. It 
directly mediates cytoadherence of Plasmodium falciparum parasitized erythrocytes, and it 
binds long chain fatty acids and may function in the transport and/or as a regulator of fatty acid 
transport (Pietka, Schappe et al. 2014). Unlike class A receptors, which recognize the oxidized 
apo-protein portion of the lipoprotein particle, CD-36 also binds to the lipid moiety of oxLDL. 
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 Binding of oxLDL to CD-36-transfected cells is inhibited by anionic phospholipid vesicles. 
Recently, CD-36 was also identified as the major receptor for LDL modified by monocyte-
generated reactive nitrogen species (Podrez, Febbraio et al. 2000). Thus, CD-36 is a 
multifaceted molecule regulating lipid homeostasis, clearing out excess oxLDL in the periphery 
through macrophage action 
Any disturbance or imbalance to this pathway may result in defective lipid metabolism, 
which may lead to metabolic diseases such as obesity and insulin resistance; cardiovascular 
complications and heart disturbances such as stroke or a heart attack.  Thus, if patients with 
any of the mentioned predispositions also suffer any kind of TBI, the inflammatory component 
may be further exacerbated via CD-36, which would be reflected by an up-regulation of CD-36 
in the brain, which is the main thesis of this study. 
   
1.4 Role of CD-36 in Atherosclerosis 
This segment will cover the prevalence, pathology, and treatment of atherosclerosis; 
followed by the role of CD-36 in lipid processing, and its inflammatory links with atherogenesis. 
Cardiovascular disease is the major cause of mortality and morbidity in developed countries and 
its prevalence is increasing in developing countries, and atherosclerosis is responsible for many 
of the severe manifestations, including myocardial ischemia, acute myocardial infarction, heart 
failure, and stroke (Sun 2014). Atherosclerosis is a disease in which plaque builds up inside 
your arteries. Arteries are blood vessels that carry oxygen-rich blood to your heart and other 
parts of your body. The plaque forms when fat, cholesterol, calcium, and other substances 
found in the blood accumulate in the arteries. Over the course of time, the plaque hardens and 
narrows arteries, limiting the flow of oxygen-rich blood to your organs and other parts of the 
body. Atherosclerosis can lead to serious problems, including heart attack, stroke, or even 
death. 
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Atherosclerosis is primarily a degenerative disorder related to aging with a chronic 
inflammatory component. It is well-known that an inflammatory process occurs within the arterial 
wall at the site of a developing plaque (van der Wal, Becker et al. 1994; Kadar and Glasz 2001; 
van der Meer, Iglesias del Sol et al. 2003). Multiple studies in the late 1980’s and early 1990’s 
identified various cellular receptors involved in binding and internalization of mLDLs known as 
“scavenger receptors.” Their physiological roles are still unclear; they presumably have a 
significant role in atherosclerotic foam cell formation (Gown, Tsukada et al. 1986; Fogelman, 
Van Lenten et al. 1988; Steinberg 1997; Steinberg, Gotto et al. 1999).The progression of early 
atherosclerotic lesions to clinically relevant advanced atherosclerotic lesions occurs with 
increased frequency in persons with risk factors for atherosclerotic disease (e.g. 
hypercholesterolemia, hypertension, cigarette smoking) (Ip, Fuster et al. 1991). Nevertheless, 
scavenger receptors, including CD-36, are thought to be most important early in the progression 
of atherosclerosis during macrophage uptake of modified LDL and foam cell formation 
(Nicholson, Han et al. 2001). Proposed mechanisms describe how LDL particles suffer an 
oxidative modification in the vessel wall by reactive oxygen metabolites produced by monocytes, 
neutrophils, and other cells in the developing lesion (Nicholson, Frieda et al. 1995; Nicholson, 
Han et al. 2001; Nicholson 2004; Nicholson and Hajjar 2004). In vivo studies in the field of 
atherosclerosis have identified key mechanisms related to the pathogenesis of this disease. For 
example, genetically engineered murine models have been used to elucidate the contribution of 
the different scavenger receptors, to identify specific ligands related to LDL modifications (Feng, 
Han et al. 2000; Nicholson, Febbraio et al. 2000; Nicholson, Han et al. 2001). There has been 
steady progress in our understanding of the regulation of expression of CD-36 and have 
demonstrated that oxLDL can stimulate its own uptake by induction of CD-36 gene expression. 
OxLDL upregulates CD-36 through a mechanism involving the activation of the transcription 
factor, PPAR‐γ.   
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Macrophages are big players of the inflammatory response. They have a scavenger 
function, internalizing cholesterol modified lipoproteins. Uncontrolled cholesterol accumulation in 
macrophages may result as an adaptive mechanism in response to excessive lipid load and 
lead to foam cell formation (Febbraio, Guy et al. 2004). These foam cell formation is part of the 
initial lesion in atherosclerosis, known as fatty streak (Lusis 2000). Oxidative modification of low-
density lipoprotein (LDL) has been hypothesized to be a key event in the conversion of LDL to a 
pro-atherogenic form recognized by macrophage scavenger receptors (Steinberg 1997; 
Kunjathoor, Febbraio et al. 2002). Thus, internalization of oxidized LDL (oxLDL) by 
macrophages is an early and potentially pivotal event which, if inhibited through intervention at 
the level of the scavenger receptor, may delay the atherosclerotic process.  An atherosclerotic 
model with chimeric mice lacking CD-36 macrophages, stem cell transplantation revealed that 
absence of macrophage CD-36 was protective against atherosclerosis. These mice lacking CD-
36 were protected against atherosclerosis, they had  88.1% reduction of lesion area throughout 
the aortic tree (Febbraio, Guy et al. 2004).  Thus, CD-36 is not just a lipid biomarker in 
cardiovascular problems; it has an inflammatory component that would help establish a 
pathological link between atherosclerosis, stroke, and TBI. Variations in CD-36 expression may 
suggest a pathological role in TBI, and its co-localization with other inflammatory markers, such 
as MCP-1 advises its correlation with an inflammatory response after trauma. Obesity is a 
comorbidity factor in stroke and TBI. CD-36 is a Fat/Lipid biomarker of obesity, stroke & 
associated disorders. Stroke and TBI have overlapping pathological events. CD-36 could be the 
pathological link between inflammation and TBI. CD-36 is a candidate therapeutic target to 
abrogate secondary cell death in TBI and promote functional and cognitive brain recovery. 
 
1.5 Role of CD-36 in Stroke 
This section will now discuss stroke prevalence, pathology, treatment, but more 
importantly it will highlight the inflammatory implications of CD-36 in animal stroke models. An 
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ischemic stroke occur when blood supply to part of the brain is suddenly interrupted or when a 
blood vessel in the brain bursts, spilling blood into the spaces surrounding brain cells. Brain 
cells die from hypoxia, lack of nutrients from the blood, from sudden bleeding into or around the 
brain. According to the American Heart Association (AHA), the hallmark symptoms of a stroke 
include: abrupt numbness or weakness, especially on one side of the body; momentary 
confusion; trouble speaking or understanding speech; disrupted vision in one or both eyes; 
problems with walking, dizziness, or loss of balance or coordination; or a severe headache with 
no known cause. There are two forms of stroke: ischemic and hemorrhagic. The first one is 
simply blockage of a vessel supplying blood to the brain, and the second one occurs when there 
is a hemorrhage into or around the brain.  
In 2008, mortality from stroke was the fourth leading cause of death in the United States, 
and stroke was a leading cause of long-term severe disability (Minino, Murphy et al. 2011). 
Nearly half of older stroke survivors experience moderate to severe disability (Kelly-Hayes, 
Beiser et al. 2003). Care for stroke survivors cost an estimated $18.8 billion in the United States 
during 2008, and lost productivity and premature mortality cost an additional $15.5 billion 
(Roger, Go et al. 2012). Ischemic stroke may arise from the atherosclerotic large cerebral 
arteries (e.g., carotid, middle cerebral, and basilar arteries) or atherosclerotic small cerebral 
arteries (e.g., lenticulostriate, basilar penetrating, and medullary arteries); ischemic stroke may 
also be cardio-embolic in origin (Reeves and Swenson 2008). In addition to thrombotic 
occlusion at the site of cerebral artery atherosclerosis and ischemic infarction can be produced 
by emboli arising from proximally situated atheromatous lesions to vessels located more distal 
in the arterial tree (Mohr and Sacco 1992). Most investigations of atherogenesis have focused 
on the coronary arteries, but, with some possible exceptions, similar processes occur in the 
cerebral circulation. 
In the brain, the process is better characterized in the larger arteries than in small 
arteries supplying deep cerebral white matter. Some evidence suggests that the underlying 
26 
pathogenetic process in small arteries may differ from that described in larger arteries (DeGraba 
TJ, Fisher M et al. 1992). A cascade of events known as “ischemic cascade” comprise:  
anaerobic metabolism within the region of brain tissue affected by ischemia; anaerobic 
metabolism produces less adenosine triphosphate (ATP) and release of lactic acid, which 
disrupts the normal acid-base balance in the brain; followed by glutamate excitotoxicity; 
mitochondrial failure, energy depletion and apoptosis. The American Heart Association and 
CDC break down treatment into three stages: prevention, therapy immediately after the stroke, 
and post-stroke rehabilitation (AHA, 2013). Prevention involves therapies that target an 
individual's underlying risk factors for stroke, such as hypertension, atrial fibrillation, and 
diabetes (CDC, 2014). Acute stroke therapies try to stop a stroke while it is happening by 
administering a thrombolytic agent; it quickly dissolves the blood clot, tissue plasminogen 
activator (TPA). TPA should be administered as soon as possible after the first stroke symptoms 
have appeared, preferably within the therapeutic window of 3 hours.  TPA improves the chances 
of recovering from a stroke. Studies have shown that patients with ischemic strokes who 
received TPA are more likely to recover fully or have less disability than patients who do not 
receive the drug (NINDS 1995; Marler, Tilley et al. 2000). In cases of hemorrhagic stroke, 
doctors will perform surgery to try stopping the bleeding. Post-stroke rehabilitation helps 
individuals overcome disabilities that result from stroke damage.  
CD-36 has been reported as an inflammatory mediator in animal models of ischemic 
stroke and hyperlipidemia (Cho, Szeto et al. 2007; Kim, Tolhurst et al. 2008; Kim, Febbraio et al. 
2012). There are studies showing that the use of antioxidant peptide, SS-31, attenuates CD-36 
pervasive action and improves ischemia-induced injury (Cho, Szeto et al. 2007). Overall these 
studies suggest that CD-36 mediated inflammation significantly contributes to the cytotoxic 
effects seen in stroke. Additionally, studies in mice and human models of ischemic stroke 
attempt to identify the benefits of a soluble form of receptor for advanced glycation end products 
(sRAGE). Plasma levels of sRAGE and high mobility group box 1 (HMGB1) were both 
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significantly increased within 48 hours after stroke, and the sRAGE level was an independent 
predictor of functional outcome at 3 months post-stroke (Tang, Wang et al. 2013). Thus, SS-31 
and sRAGE may have potential therapeutic effects in stroke and related inflammatory disorders. 
Because of overlapping cell death events between stroke and TBI, the molecular 
pathways of secondary cell death implicated in stroke may also be involved in the progression 
of TBI. The release of pro-inflammatory cytokines by microglia is a major feature occurring in 
stroke and TBI.  Similarly, previously mentioned therapies found effective in arresting the 
secondary cell death in stroke may also be valuable therapies for TBI.  Since CD-36 closely 
accompanies stroke-induced neuroinflammation, and that neuroinflammation is a major cause 
of secondary cell death in TBI, then it is likely that investigations of CD-36 in TBI will provide 
novel insights into the understanding of TBI neuroinflammation. Moreover, targeting CD-36 may 
prove effective in attenuating neuroinflammation and therefore stands as a potent therapeutic 
pathway for treatment of TBI.  
Furthermore, in animal models of ischemia/reperfusion injury oxLDL high levels activate 
CD-36, increasing free radical production and tissue injury. In a recent murine ischemic study, 
scientists tested an antioxidant peptide, SS-31 a cell permeable peptide that may reduce 
intracellular free radicals and inhibits LDL oxidation/lipid peroxidation (Zhao, Zhao et al. 2004). 
In addition, treating mice with SS-31 immediately after reperfusion significantly attenuated 
ischemia-induced GSH depletion in the cortex and reduced infarct size; no protective effect of 
SS-31 was observed in CD-36 knock-out mice, indicating that SS-31 is acting through inhibition 
of CD-36; and treating C57BL/6 mice with SS-31 reduced CD-36 expression in post-ischemic 
brain and mouse peritoneal macrophages (MPM) (Cho, Szeto et al. 2007) . These in vivo and in 
vitro studies suggest the down-regulation of CD-36 by novel class antioxidant peptides may be 
used to treat ischemia and possibly TBI, too.  Thus, we will address the pharmacological effects 
of sRAGE in an in-vitro model of TBI.  
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1.6 Role of CD-36 in TBI  
Although a neuroinflammatory connection has been established between CD-36 with 
stroke and other degenerative diseases, there is very little information or experimental reports 
connecting CD-36 with TBI. We will review this literature and address the series of in-vitro and 
in-vivo experiments previously carried by Borlongan’s lab team supporting our notion: CD-36 
could be the pathological link between inflammation and TBI. Recent  publications have 
documented diabetes mellitus (DM) as a co-morbidity factor in TBI (Cerecedo-Lopez, Kim-Lee 
et al. 2014), and diabetes Insipidus (Diamandis, Gonzales-Portillo et al. 2013) contributing  to 
TBI pathology via CD-36 neuroinflammation.  
A series of in-vitro experiments focused first on the ability of soluble receptor of 
advanced glycation end products RAGE (sRAGE) in binding CD-36-oxLDL in cells of different 
origin.  They decided to test  sRAGE because of its strong affinity for CD-36 (Marsche, 
Zimmermann et al. 2003),  its synergistic anti-inflammatory effect combined with long term use 
of antihypertensive drugs like nifedipine and telmisartan (Falcone, Buzzi et al. 2012); and 
sRAGE ability to act as a decoy for RAGE to slow carotid artery bloom injury, slow 
atherosclerosis via blocking RAGE, and avoid interaction of RAGE with its pro-inflammatory 
ligands (AGEs, HMGB1, S100 proteins) (Maillard-Lefebvre, Boulanger et al. 2009).  
It is well documented the spleen immune function is known to alter stroke outcome. 
Additionally, this immune response parallels with observed downstream pro-survival 
(neurogenesis) and cell death events (neurovascular alterations revealed by matrix 
metalloproteinaises breakdown and inflammatory response) over the same 24-48 hour period 
(Hayashi, Kaneko et al. 2009; Shojo, Kaneko et al. 2010). 
  This evidence implies that sRAGE is a useful inhibitor of CD-36 mediated inflammation 
response in brain and spleen of TBI animals. We were able to determine the inhibitory action of 
soluble receptor of advanced glycation end products (sRAGE) in various cell types, suggesting 
that sRAGE antagonistic effects may be a useful strategy to reduce CD-36 mediated uptake of 
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HOCl-LDL, and attenuate the immune response and tissue injury. These pilot experiments 
further bolster the role of CD-36 mediated inflammation as a major secondary cell death 
mechanism shared by stroke and TBI. Accordingly, we hypothesize that CD-36 has a pivotal 
role in the neuroinflammatory cascade that further contributes to the pathology of TBI. Exploiting 
this CD-36 mechanism as a candidate therapeutic target will abrogate secondary cell death in 
TBI and promote functional and cognitive brain recovery. Furthermore, the therapeutic inhibitory 
effects of sRAGE on CD-36 expression highlight a possible therapeutic window when 
administered within 24 hours post-TBI. 
 
1.7 Role of CD-36 in Other Neurodegenerative Diseases 
We will address the different pathological scenarios in which CD-36 has been found to 
take participate in neurodegenerative diseases. Recent studies have associated CD-36 to 
inflammatory alterations in Alzheimer’s disease (AD), cerebral amyloid angiopathy (CAA), and 
Parkinson’s disease (PD). We will address the inflammatory pathways associated with CD-36 
among the mentioned disorders, and strengthen the notion of CD-36 as a therapeutic target.  
 
1.7.1 Alzheimer’s Disease 
AD is a neurodegenerative disease (AD) characterized by the accumulation of a protein 
known as amyloid-β (Aβ) in the brain. Patients experience serious memory loss, confusion, 
mood and behavior changes. According to reports by the Alzheimer's Association  (AA), the 
National institute of Aging, the CDC and recent  statistical literature an estimated 5.2 million 
Americans are suffering from AD in 2014, including approximately 200,000 individuals younger 
than age 65 who have younger-onset Alzheimer's (Brookmeyer, Evans et al. 2011; Innes and 
Selfe 2014; Weuve, Hebert et al. 2014). Of the 5 million people age 65 and older with AD in the 
United States, 3.2 million are women and 1.8 million are men (Mielke, Vemuri et al. 2014). The 
mentioned institutions estimate that by 2050, the number of people age 65 and older with AD 
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may nearly triple, from 5 million to as many as 16 million, making impossible to advance  in 
medical innovations to prevent, delay or stop the disease (Alzheimer's Association 2013). To 
put things into perspective and draw a clearer picture on the urgency for effective care, Florida 
alone reported close to 500,000 patients struggling with TBI and associated costs close to 600 
thousand millions (Gilligan, Malone et al. 2013). Nationwide analysts from the AA predict costs 
will climb from $214 billion in 2014 to $1.2 trillion by the midcentury.  
The pathology of AD is very complex. It consists in the formation of amyloid plaques and 
cerebral amyloid angiopathy, neurofibrillary tangles, and glial responses, and detrimental 
lesions such as neuronal and synaptic loss (Hyman, Phelps et al. 2012). Many neuroscientists 
have suggested further labeling as “positive lesions” amyloid plaques and CAA, neurofibrillary 
tangles, and glial responses (Serrano-Pozo, Frosch et al. 2011). In contrast, the “negative 
lesions” are characteristic losses of neurons, neuropil, and synaptic elements (DeKosky and 
Scheff 1990; Scheff, DeKosky et al. 1990; Terry, Masliah et al. 1991; Masliah, Mallory et al. 
1993; Scheff and Price 1993; Gomez-Isla, Price et al. 1996; Knowles, Wyart et al. 1999; 
Serrano-Pozo, Frosch et al. 2011). Yet, no one has linked CD-36 to any of the negative lesions 
listed above, but there are reports linking CD-36 to Aβ protein deposition (Ricciarelli, D'Abramo 
et al. 2004) and CAA (Park, Zhou et al. 2013). Ricciarelli and his collaborators revealed some 
interesting results: first mRNA and protein CD-36 expression was highly expressed in the 
cerebral cortex of AD patients and cognitively normal aged subjects with diffuse amyloid 
plaques compared with age-matched amyloid-free control brains. Thus, CD-36 expression in 
human brain correlates with the presence of amyloid plaques. Second, in-vitro experiments by 
the same team investigated whether Aβ1-42 may modulate the expression of CD-36; surely 
enough after 24 hours of treatment the mRNA levels of CD-36 were upregulated in 
neuroblastoma and human monocytes, but to a less extent on primary rat neurons. Likewise, 
Borlongan’s team found human monocytes (not treated with sRAGE) expressed a strong 
association with CD-36 ox-LDL.  The third major finding being the more important, the induction 
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of CD-36 in these cell lines lasted after 48 hrs, denoting the first evidence of CD-36 expression 
in cells of neuronal origin (Ricciarelli, D'Abramo et al. 2004). 
Besides Aβ aggregation in the brain, AD patients also have a strong inflammatory 
component with increased microglia activation. Wilkinson and Khoury describe how microglia 
and Aβ have a dichotomous role  in AD pathogenesis (Wilkinson and El Khoury 2012). On one 
hand, microglia can phagocytose and clear Aβ, but binding of microglia to Aβ also increases 
their ability to produce inflammatory cytokines, chemokines, and neurotoxic reactive oxygen 
species (ROS) (Pan, Zhu et al. 2011; Wilkinson and El Khoury 2012). But who is responsible for 
clearing Aβ? Scavenger receptors.  Microglia carries receptors for Aβ, in particular: SCARA-1 
(scavenger receptor A-1), CD-36, and RAGE (receptor for advanced glycation end products) 
(Wilkinson and El Khoury 2012). CD-36 has been implicated in a mechanism  of fibrillar Aβ 
internalization along with α6β1 integrin and the integrin associated protein CD-47 
(Koenigsknecht and Landreth 2004). SCARA-1 appears to be involved in the clearance of Aβ 
(Herber, Mercer et al. 2007; Napoli and Neumann 2009); while CD-36 and RAGE are involved 
in activation of microglia by Aβ (Scheff 1990). A second team reported that SR-A and CD-36 
had similarities between interactions of microglia with fibrillary Aβ and of macrophages with 
oxLDL in brains of AD patients (Coraci, Husemann et al. 2002). Altogether above experiments 
are compelling evidence that CD-36 participates in Aβ protein aggregation and inflammatory 
signaling pathways of AD.  No cure or treatment exists that can reverse the effects of AD. 
Medical treatment appeared in the 1990’s. Nevertheless, these pharmacological drugs alleviate 
symptoms but cannot stop the progression of the disease. Current FDA-approved Alzheimer's 
drugs, cholinesterase inhibitors and (N-methyl-D-aspartate) receptor (NMDA) antagonist do not 
suffice. The positive effects of 1) cholinesterase inhibitors (donepezil, galantamine, rivastigmine 
and tacrine) work by slowing down the disease activity that breaks down acetylcholine 
(Kaduszkiewicz, Zimmermann et al. 2005; Hansen, Gartlehner et al. 2008; Parsons, Danysz et 
al. 2013); and 2) memantine protects brain cells against excess glutamate released in large 
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amounts by cells damaged by Alzheimer's disease and other neurological disorders (Schneider, 
Insel et al. 2011; Danysz and Parsons 2012). Thus, the study of inflammatory alterations of CD-
36 in AD, CAA, and TBI can help reduce the gap in knowledge of signaling molecules 
influencing microglia activation via CD-36. 
 
1.7.2 Cerebral Amyloid Angiopathy 
With respect to CAA Park and his collaborators observed that Tg2576 mice lacking CD-
36 have a selective reduction in Aβ1-40 deposition and CAA, reduced vascular amyloid 
deposition was associated with preservation of the Aβ vascular clearance receptor LRP-1, and 
protection from the deleterious effects of Aβ on cerebral arterioles; these beneficial vascular 
effects were reflected by marked improvements in neurovascular regulation and cognitive 
performance  (Park, Zhou et al. 2013). Once again, there is clear evidence suggesting CD-36 
participates in the pathology of vascular amyloid deposition, and as a potential therapeutic 
target.  
 
1.7.3 Parkinson’s Disease  
A second disease whose pathology may have a CD-36 inflammatory component is PD. 
This disease is a neurodegenerative disorder characterized by the progressive degeneration of 
dopaminergic neurons in the substantia nigra; leading to diminished striatal dopamine levels, 
and the appearance of proteinaceous inclusions known as Lewy bodies (Abumrad and Moore 
2011). There is a genetic predisposition to the disease associated with mutations in the parkin 
gene. Parkinson disease (PD) affects 1%–2% of the world’s population over the age of 65 years 
(Willis 2013). Common symptoms of PD include bradykinesia, resting tremor, muscular rigidity, 
and postural instability; in addition, non-motor symptoms include autonomic, cognitive, and 
psychiatric disturbances (Cohen, Klein et al. 2014). There are no available treatments that can 
cure PD, only pharmacological agents, levodopa combined with carbidopa, that attenuate the 
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symptoms. Yet, there is a collaborative effort of 7 translational clinical trials in th US trying to 
identify new indicators of disease progression, these PD candidates may be present at early 
and late PD stages of the disease, and are being measured in different body fluids like CSF and 
blood collected from patients with PD and healthy control subjects. 
Kim and colleagues identified CD-36 as a new substrate of Parkin-mediated 
ubiquitination and propose a potentially broad function of Parkin in the regulation of FA 
metabolism (Kim, Stevens et al. 2011). Additionally, CD-36 bind certain ligands eliciting a range 
of intracellular signaling processes involving Src and MAP kinases that integrate lipid 
metabolism and inflammation and also involve CD-36 in pathways related to oxidative stress, 
angiogenesis, platelet hyperactivity, phagocytosis, and cell migration (Silverstein and Febbraio 
2009; Su and Abumrad 2009). Importantly, CD-36 membrane levels and turnover are abnormal 
in diabetes, resulting in dysfunctional FA utilization. In addition, variants in the CD-36 gene were 
shown recently to influence susceptibility for the metabolic syndrome, which greatly increases 
the risk of diabetes and heart disease. In summary, these studies provide insights into the 
connection between neurodegenerative disorders and lipid metabolism. Additional experiments 
will strengthen the link between chronic neurological disorders and CD-36. 
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CHAPTER 2 
MATERIAL AND METHODS 
 
 The experiments are designed to test our hypothesis that CD-36 has a pivotal role in the 
neuroinflammatory cascade that further contributes to the pathology of TBI. Exploiting this CD-
36 mechanism as a candidate therapeutic target will abrogate secondary cell death in TBI may 
promote functional and cognitive brain recovery. We postulate the following aims: (1) CD-36 is a 
critical mediator of neuroinflammation following TBI in the cortex, this secondary cell death 
mechanism may be reflected in the progressive expression of CD-36 in the spleen, providing a 
key pathological link between peripheral regulation of brain injury. Aim 1 studied TBI at two 
disease stages: (1.1) CD-36 mediated inflammation in acute TBI, without therapeutic 
intervention, translates to (1.2) chronic neuroinflammation and it was recognized via 
upregulation of neuroinflammation during disease progression. In order to test this hypothesis, 
we characterized CD-36 expression in the brain and the spleen of TBI animals in acute and 
chronic stages of injury thru histological and immunoblotting analysis described below (sections 
2.1-2.12). The above in vivo testing is preferred over in vitro because it is more suitable for 
observing the overall effects of CD-36 on a living organism. In addition, Aim 2 addresses 
pharmacological interventions to inhibit inflammation in an in vitro TBI model. Experiments 
attempted an inhibitory approach to reduce TBI related inflammation and secondary cell death 
using sRAGE (section 4.2). Furthermore, Aim 3 examined the use of stem cell therapy in 
combination with sRAGE to abrogate neuroinflammation in an in-vitro TBI model (section 5.2).  
 First, we characterized histological symptoms of TBI, with emphasis on 
neuroinflammation, in acute (Aim 1.1) and chronic (Aim 1.2) stages of the injury. Procedures 
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outlined in sections 2.1 thru 2.13 tested these sub aims. At the completion of these experiments 
we would have gained a better understanding on the role of brain and splenic CD-36 
contributing to TBI neuroinflammation. The last section 2.14 briefly describes previous 
preliminary in-vitro experiments performed by our team on CD-36.  
 
2.1 Animals 
 Studies in Sprague-Dawley (SD) rats were carried in accordance with the 
recommendation in the Guide for the Care and Use of Lab oratory Animals of the National 
Institutes of Health. The protocol was approved by the Institutional Animal Care and Use 
Committee (IACUC) at the University of South Florida, College of Medicine. All male rats were 
housed under normal conditions (20°C, 50% relative humidity, and a 12-hrs light/dark cycle). A 
separate cohort of animals, sham group, underwent the same experimental conditions. Only 
male Sprague-Dawley rats were used in this study, and housed under normal conditions. 
Necessary precautions were taken to reduce pain and suffering of animals throughout the study. 
Next, we embarked on the animal surgical procedures for modeling of the disease to reproduce 
many of the features observed in TBI in humans. 
 
2.2 Surgical Procedures 
 The controlled cortical impact model in animals is an effective experimental tool to 
replicate what happens to humans after TBI. Ten week old, male Sprague-Dawley rats (n=60) 
were subjected to mild TBI using the controlled cortical impact (CCI) injury model (Pittsburgh 
Precision Instruments, Inc, PA, USA). Animals were anesthetized using 1–2% isoflurane. Once 
deep anesthesia was achieved, individual animals were fixed in a stereotaxic frame (David Kopf 
Instruments, Tujunga, CA, USA), anesthesia was maintained via gas mask. TBI injury surgeries 
consisted of animals subjected to scalp incision to expose the skull, using an electrical drill a 
4.0mm craniectomy was performed over the  right frontoparietal cortex (2.0 mm anteroposterior 
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(AP),+2.0 mm mediolateral (ML), and 1.0 mm dorsoventral (DV) to bregma (Paxinos G 2005; 
Glover, Tajiri et al. 2012). The pneumatically operated TBI device (with a convex tip diameter of 
3.0 mm for rats) impacted the brain at a velocity of 6.0 m/s reaching a depth of 1.0 mm for mild 
TBI, below the dura mater layer and remained in the brain for 150 milliseconds (ms). The 
impactor rod was angled 15° degrees to the vertical to maintain a perpendicular position in 
reference to the tangential plane of the brain curvature at the impact surface (Yu, Kaneko et al. 
2009). A linear variable displacement transducer (Macrosensors, Pennsauken, NJ) connected 
to the impactor measured velocity and duration to verify consistency.  This CCI approach 
produced skull fracture overlying the frontal cortex. All animals received the analgesic 
ketoprofen (5mg/kg of weight) post-operatively. Rats were monitored closely. Next, TBI animals 
and sham animals were grouped and sacrified at various post TBI time-points for subsequent 
histological and protein analysis to determine CD-36 alterations.  
 
2.3 Histology 
 Under deep anesthesia, rats were sacrificed at different time-points: 24 hours (hrs), 48 
hrs, 7 days, and 60 days post-TBI surgery, along with their corresponding sham groups. All 
animals underwent transcardial perfusion, rats were placed on their backs, and blunt forceps 
were used to cut through the body cavity. The opening was extended laterally until reaching the 
rib cage. Rib cage was cut, and sternum was lifted to expose the heart. The heart was held 
gently, and the needle was inserted ¼ inch into the left ventricle. The right atrium was cut using 
the irridectomy scissors. Through the ascending aorta, approximately 200 ml of ice cold 
phosphate buffer saline (PBS) followed by 200 mL of 4% paraformaldehyde (PFA) in phosphate 
buffer (PB) were used for brain perfusion. Sham animal groups underwent the same procedure. 
 Brains and spleens were removed and post-fixed in the same fixative at 4°C for 24 hrs 
followed by two rounds of 30% sucrose in PB for 48 hrs. Brains were frozen at −24°C, mounted 
onto a 40 mm specimen disk using embedding medium. Coronal sectioning was carried out at a 
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thickness of 30 µm by cryostat on every 6th (1/6) coronal section spanning the prefrontal cortex 
up to the entire dorsal hippocampus, starting at coordinates AP +2.70mm and ending at AP-
3.0mm relative to bregma. Coronal cryostat sections were stored in a cryoprotectant solution at 
20°C until immunohistochemical staining to address sub-aims 1.1. and 1.2. 
 
2.4 Tissue Collection for Protein Analysis  
A second set of animals were sacrificed at different time-points under deep anesthesia: 
24 hours (hrs), 48-hrs, 7 days, and 60 days post-TBI surgery, along with their corresponding 
sham groups. All animals underwent transcardial perfusion, rats were placed on their backs, 
and blunt forceps were used to cut through the body cavity. The opening was extended laterally 
until reaching the rib cage. Rib cage was cut, and sternum was lifted to expose the heart. The 
heart was held gently, and the needle was inserted ¼ inch into the left ventricle. The right atrium 
was cut using the irridectomy scissors. Through the ascending aorta, approximately 300 mL 
cold phosphate buffer saline (PBS) were used for brain perfusion. Sham animal groups 
underwent the same procedure. Brain tissue was dissected into main brain regions: cortex, 
striatum, dorsal and ventral hippocampus  (Chiu, Lau et al. 2007). Immediately tissue sections 
and spleens were placed in individual cryoprotectant vials in liquid nitrogen (-196°C) and 
transferred to a -80°C freezer. Accordingly, histological and protein analysis experiments of CD-
36 expression in the brain, as well as in the spleen may reveal more detail about the central and 
peripheral CD-36 inflammatory response after TBI. Neuroinflammation is a double-edged sword, 
in that inflammatory signals (i.e., anti-inflammatory) may be upregulated at the acute phase, but 
a different set of inflammatory cues (i.e., pro-inflammatory) will be elevated at the chronic 
phase. Thus, we covered various immunohistochemical stainings in sections 2.5.1-2.5.5 to 
capture for any other upregulated inflammatory markers in brain and spleen. After these 
experiments, we analyzed brain tissue through confocal microscopy (section 2.6) to quantify the 
number of CD-36 positive reactive cells; and spleen tissue through fluorescence microscopy 
38 
(section 2.7) to measure fluorescence intensity. And finally, statistical analysis was carried on 
the brain data to compare any significant differences among the ipsilateral vs contralateral 
hemispheres of the injured brain animals, and against sham brains, too (section 2.8). With 
respect to the spleen data, statistical analysis was also carried for TBI vs. sham animals 
(section 2.9). 
 
2.5. Immunohistochemistry  
  
2.5.1 CD-36/MCP-1 Immunohistochemistry in Brain  
 A series of one in six sections was selected that included the anatomical region of 
interest (from prefrontal cortex to hippocampus) with a random start section for each subject for 
this staining. On day one free-floating sections (30µm thickness) were incubated with mouse 
monoclonal anti CD-36 (1:100, Abcam, USA), rabbit polyclonal anti MCP-1 (1:100, Abcam, 
USA) primary antibodies overnight at 4C, followed by day two incubation with goat anti-mouse 
secondary antibody (1:1000 Alexa 488, Molecular Probes, USA), and goat anti-rabbit secondary 
antibody (1:1000-2000 Alexa 594, Molecular Probes, USA) for 2 hrs at RT. Finally, tissue was 
incubated with Hoechst 33258 (bisBenzimideH 33258 trihydrochloride) for 30min (1:300 
Molecular Probes, USA) to visualize cell nuclei. Then tissue underwent three washes in PBS, 
and coverslipped with Fluoromount (Sigma). 
 
 2.5.2 CD-36/Iba-1 Immunohistochemistry in Brain  
 A series of one in six sections was selected that included the anatomical region of 
interest (from prefrontal cortex to hippocampus) with a random start section for each subject for 
this staining. On day one free-floating sections (30µm thickness) were incubated with mouse 
monoclonal anti-CD-36 (1:100, Abcam, USA), and rabbit polyclonal anti Iba-1 (1:300, WAKO, 
Japan) primary antibodies overnight at 4°C. The next day tissue was incubated for 2 hrs in goat 
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anti-mouse secondary antibody (1:1000 Alexa 488, Molecular Probes, USA) and goat anti-rabbit 
secondary antibody (1:1000-2000 Alexa 594, Molecular Probes, USA), followed by incubation 
with Hoechst (bisBenzimideH 33258 trihydrochloride) for 30 mins (1:300 Molecular Probes, 
USA), then tissue underwent three washes in PBS for 30 mins, and coverslipped with 
Fluoromount (Sigma). 
 
 2.5.3 CD-36/NeuN Immunohistochemistry in Brain  
 A series of one in six sections was selected that included the anatomical region of 
interest (from prefrontal cortex to hippocampus) with a random start section for each subject for 
this staining. On day one free-floating sections (30µm thickness) were incubated with mouse 
monoclonal anti-CD-36 (1:100, Abcam, USA), and rabbit monoclonal anti-NeuN (1:500, 
Millipore, USA) primary antibodies overnight at 4C. The next day tissue was incubated for 2 hrs 
in goat anti-mouse secondary antibody (1:1000 Alexa 488, Molecular Probes, USA) and goat 
anti-rabbit secondary antibody (1:1000-2000 Alexa 594, Molecular Probes, USA), followed by 
incubation with Hoechst (bisBenzimideH 33258 trihydrochloride) for 30 mins (1:300 Molecular 
Probes, USA), then tissue underwent three washes in PBS for 30 mins, and coverslipped with 
Fluoromount (Sigma). 
 
 2.5.4 CD-36/GFAP Immunohistochemistry in Brain 
 A series of one in six sections was selected that included the anatomical region of 
interest (from prefrontal cortex to hippocampus) with a random start section for each subject for 
this staining. On day one free-floating sections (30µm thickness) were incubated with mouse 
monoclonal anti CD-36 (1:100, Abcam, USA), and rabbit polyclonal anti-GFAP (1:2000, DAKO, 
USA) primary antibodies overnight at 4C. The next day tissue was incubated for 2 hrs in goat 
anti-mouse secondary antibody (1:1000 Alexa 488, Molecular Probes, USA) and goat anti-rabbit 
secondary antibody (1:1000-2000 Alexa 594, Molecular Probes, USA), followed by incubation 
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with Hoechst (bisBenzimideH 33258 trihydrochloride) for 30 mins (1:300 Molecular Probes, 
USA), then tissue underwent three washes in PBS for 30 mins, and coverslipped with 
Fluoromount (Sigma). 
 
 2.5.5 CD-36 Immunohistochemistry in Spleen 
 Spleen sectioning was carried out at a thickness of 20 µm by cryostat at -19°C. 
Fluorescent immunostaining was done on every 6th (1/6) coronal section and mounted directly 
onto the slide. Day one involved incubating tissue sections with mouse monoclonal anti-CD-36 
(1:100, Abcam, USA) overnight. The next day, tissue slides were incubated in goat anti-mouse 
secondary antibody for 2 hrs (1:1000 Alexa 488, Molecular Probes, USA). Then, tissue was 
washed 3 times for 10 mins and coverslipped with DAPI H-1200 mounting medium 
(Vectashield). 
 
2.6 Laser Scanning Confocal Microscopy 
 A multiphoton laser confocal scanning microscope (FV1000 MPE, Olympus, USA) was 
used for observation and imaging for all immunofluorescence photomicrographs of the motor 
cortex area(M1, M2) at a 40x magnification, only linear adjustments (brightness and contrast) 
were made to the figures. When quantification of percentage of positive cells was determined, Z 
stacks were created at 1 µm intervals throughout the 30 µm of the sections with a guard region 
of 2 mm excluded from top and bottom of the Z stack. The Z stacks were rotated in all planes to 
verify double labeling. 
 
2.7 Fluorescencent Microscopy   
A fluorescent microscope (Axio Imager.Z1, Zeiss, USA) was used for observation and 
imaging of spleen slides at a 40x magnification. Six serial spleen coronal sections were 
quantified using Image J and results are displayed as the average mean of fluorescent intensity. 
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2.8 Statistical Analysis on Indirect Immunofluorescence in Brain 
 CD-36, MCP-1, Iba-1 , Hoechst positive cells, adjacent to impact area (M1 motor cortex 
area)were counted using Image J using 6 serial coronal sections, results showed the average 
mean of the  cell ratios of CD-36/DAPI, (CD-36 + MCP-1 cells)/MCP-1, MCP-1/DAPI, CD-
36/DAPI,Iba-1/DAPI, CD-36/Iba-1. Likewise, the contralateral side of injured brains, and sham 
brains were analyzed.  Explored coronal sections correspond to +2.7 to -0.3 mm with respect to 
bregma. The data obtained were analyzed using the Graph Pad Prism 5.0 software, and were 
evaluated statistically using one way analysis of variance (ANOVA) for group comparisons with 
95% CI followed by subsequent pair wise comparisons using post hoc Bonferonni test. All data 
are presented as mean values ±SEM. Statistical significance was set at p<0.05 for all analyses. 
 
2.9 Statistical Analysis on Fluorescence Intensity in Spleen 
 The data obtained was analyzed using the Graph Pad Prism 5.0 software to run the 
unpaired t-test with Welch’s correction to compare spleen from TBI animals vs. Sham animals. 
Immunoblotting or western blotting is a technique helpful for the analysis of individual proteins in 
a protein mixture or tissue lysate. We used this method to detect the expression levels of CD-36 
protein in brain and spleen at the different acute TBI time-points. Sections 2.10 thru 2.12 cover 
the process of tissue collection, homogenization and protein detection to sort the proteins by by 
size, charge. Once separated, proteins are then transferred to a carrier membrane, and 
accessible for antibody binding for detection. 
 
2.10  Tissue Processing 
 Tissue from the cortex and spleen were homogenized using an electric tissue 
homogenizer in 1:10 weight to volume ratio of ice-cold RIPA buffer (Cell Signaling Technology, 
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USA) containing 1% protease inhibitor cocktail (Sigma-Aldrich, USA). Following 
homogenization, sample lysates were centrifuged at 10,000rpm at 4ºC for two rounds of 30 
mins.  Pellets were discarded and the supernatant was then aliquoted in 50μl samples and 
stored at -80°C. 
  
2.11 Western Blot 
 BCA protein assay (BCA Protein Assay, Pierce, USA) was applied to determine total 
protein concentration for each fraction sample. Pre-cast electrophoresis gels (4-15% Mini 
Protean TGX, Bio-Rad, USA) were loaded with 30μg of total protein per sample per well, and 
current applied at 70V for 45min, resuming at 100V for 30min.  Proteins were transferred to 
nitrocellulose membranes (Bio-Rad, USA) using a Criterion blotter (Bio-Rad, USA), at 100V, for 
30 mins. The membranes were pre-incubated in 5% non-fat dairy milk (NFDM)/Phosphate 
Buffered Saline (PBS, Pierce, USA)/0.05% Tween 20 (PBST, Fisher-Scientific, USA) for 1hr, 
then incubated overnight at 4°C with one of the following primary antibodies: rabbit monoclonal 
CD-36 (1:250, Abcam, USA); mouse monoclonal GAPDH (1:25,000). The next day, membranes 
were washed with PBST, incubated with the corresponding secondary antibody): goat anti-
rabbit IR Dye 800 (1:3000, LICOR, USA) and goat anti mouse 680 (1:25,000, LICOR, USA), 
during 2 hrs, at RT. The membranes were thoroughly washed with PBST, and placed into an 
Odyssey infrared imager (LICOR, USA) for band detection. Images were analyzed through the 
Image Studio software (LICOR, USA) for band density measurements. The band density ratios 
from TBI vs.Sham groups were statistically compared. 
 
2.12 Statistical Analysis on Western Blot 
 The data obtained were evaluated statistically using one way analysis of variance 
(ANOVA) for group comparisons with 95% CI followed by subsequent pair wise comparisons 
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using post hoc Bonferonni test. All data are presented as mean values ± SEM. Statistical 
significance was set at p<0.05 for all analyses.  
The next set of experiments addressed Aims 2 and 3 using an in vitro cell model of TBI. 
We performed a pharmacologic approach using sRAGE, an inhibitor of CD-36, to reveal 
whether inhibiting this pathway produced parallel alterations in the downstream anti-
inflammatory effects of CD-36 seen in Aim 1. We replicated TBI in this in-vitro cell model by 
treating human neural progenitor cells with tumor necrosis alpha (TNF-a). We expect that this 
upstream inhibitory approach blocks the suggested inflammatory biomarker and observe 
positive effects in the survival of human neural progenitor cells.  
 
2.13 Cell Culture  
 Cultures of human neural progenitors were maintained in culture following the supplier’s 
protocol (hNP1, Neuromics, Edina, MN). Briefly, immediately after thawing, cells 
(46104cells/well) were seeded and grown in 96-well plate coated by poly-L lysine in Neurobasal 
media (GIBCO, CA) containing 2 mM L- glutamine, 2% B27 (GIBCO, CA) and 50 U/ml penicillin 
and streptomycin for 4 days at 37uC in humidified atmosphere containing 5% CO2. Cells were 
grown in confluence for 72 hrs to achieve expansion with 61%viability. These cells were 
exposed to TNF-a insult which closely simulates mild traumatic brain injury in humans. 
 
 2.13.1 Measurement of Cell Viability: Calcein-AM Fluorescence Dye 
 Measurement of cell viability was performed by both fluorescent live/ dead cell assay 
(Bell, Cao et al. 2003) exclusion method.  A two-color fluorescence cell viability assay was 
performed by Calcein-AM (Invitrogen, L3224) to be retained within live cells, including an 
intense uniform green fluorescence and ethidium homodimer (EthD-1) to bind the nuclei of 
damaged cells (bright red fluorescence).  After two hours reperfusion, the human Neural 
Progenitor Cells (hNP1, Neuromics, Edina, MN) were incubated with 2 mM Calcein-AM and 4 
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mM EthD-1 for 45 min at room temperature in darkness according to the manufacturer’s 
instructions.  The green fluorescence of the live cells was measured by the Gemini EX 
florescence plate reader (Molecular Device), excitation at 485 nm and emission at 538 nm.   
 
 2.13.2 Measurement of Mitochondrial Activity: MTT Assay  
 For the mitochondrial activity assay, reduction of 3-(4, 5-dimethyl-2-thiazoyl)-2,5-
diphenyltetrazolium bromide (MTT) by cellular dehydrogenases was used as described in our 
previous report (Kaneko, Shojo et al. 2014). The purpose of the MTT assay is to assess cell 
viability after treating cells with stem cells and sRAGE. 
 
2.14 Preliminary in Vitro and In Vivo Experiments 
 
 2.14.1 In Vitro Study CD-36 and sRAGE Expression 
 In vitro cell culture studies included: RAW cells derived from mouse tumor, Chinese 
hamster  ovary (CHO) cells expressing murine scavenger receptor class B, type I (SR-BI, 
termed CHO-SR-BI), or human CD-36 (termed CHO-CD-36), and human spleen-derived 
monocytes/macrophages (MD cells). All treatment conditions performed 
in quadruplicates.  
 
 2.14.2 CD-36, Spleen and TBI 
 Adult (2 months old) or neonatal (7 days old) Sprague-Dawley rats were subjected to 
TBI, respectively, displayed upregulated and downregulated expression of CD-36 in the spleen 
and brain at the supra-acute phase of injury (15 minutes after TBI) (Asterisk * p< 0.05 vs. 
control. Sample size was n=20 per treatment group. 
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 2.14.3 TBI and CD-36 Immune Response in Neonatal Rats.  
 Neonatal (7 days old) Sprague-Dawley rats underwent TBI and sacrificed at different 
time points to measure expression of CD-36 in the spleen and brain at 15 minutes, 3 hours,12 
hours,24 hours, and 48 hours post-TBI. Different cohorts of TBI rats were randomly euthanized 
at each time point to reveal CD-36 expression. Sample size is n=6 treatment group. Controls 
were age-matched rats that received sham surgery. Asterisk * p< 0.05 vs. control.  
 
2.14.4 Soluble RAGE Modulates CD-36 Expression in Neonatal Spleen and Brain 
after TBI.  
 In vivo model of neonatal TBI involved sRAGE treatment (25 ug/ 0.25 ml intraperineal 
injection) at 15 mins, 3 hours, 12 hours, and 24 hours) or its equivalent volume of diluent (PBS) 
was performed in neonatal Sprague-Dawley rats (7 days old). Animals were euthanized at 48 
hours post-TBI for spleen and brain analysis of CD-36 expression. Asterisk * p<0.05 vs. 
controls. Controls were age-matched rats that received sham surgery. Sample size was n=20 
per group.  
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CHAPTER 3 
INFLAMMATORY ROLE OF CD-36 IN AN ANIMAL MODEL OF TBI 
 
3.1 Introduction 
 
3.1.1 Why study CD-36 as a Biomarker of Inflammation?   
The purpose of Aim 1 is to characterize any inflammatory alterations related to CD-36 in 
an adult rat model of mild TBI. Investigations of CD-36 as a novel neuroinflammatory marker in 
TBI derive from existing literature implicating this molecule in disorders such as obesity, 
atherosclerosis, inflammation in cerebral ischemia, and certain neurodegenerative diseases 
(Coraci, Husemann et al. 2002; Kunjathoor, Febbraio et al. 2002; Cho, Park et al. 2005; Cho, 
Szeto et al. 2007; Cho and Kim 2009; Kim, Febbraio et al. 2012; Pietka, Schappe et al. 2014). 
These disorders are well known risk factors for developing debilitating disorders among 
humans. We propose CD-36 as a therapeutic target after TBI since it is a common denominator 
implicated in the inflammatory response associated with the above disorders. Studies focusing 
on CD-36 may provide insights in future pharmacological or genetic strategies to block the 
deleterious expression and function of CD-36 to treat not just TBI patients, but also those 
afflicted by previously mentioned risk factors. 
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3.1.2 Inflammatory Pathways Related to CD-36. 
CD-36 is a glycoprotein also known as fatty acid translocase (FAT). It belongs to the 
class B scavenger receptor family whose main function is to capture mLDLs. The CD-36 gene is 
encoded in chromosome 7 in humans, chromosome 4 in rats, and chromosome 5 in mice 
(GENE 2014).  This protein is extensively glycosylated with a molecular weight of 88kDa and 
also exists as a non-glycosylated version  of 53kDa (Cho, Park et al. 2005).  Among its 
functions, CD-36 contributes to the uptake of free fatty acids facilitating their transport inside of 
cells; it binds with high affinity to oxidized lipids from LDLs, advanced glycated proteins, 
components of apoptotic cells, and cell-derived micro-particles (Goldberg, Eckel et al. 2009; 
Silverstein and Febbraio 2009). However, functions of CD-36 go beyond lipid metabolism and 
cell adhesion.  
CD-36 has various ligands linked to signaling pathways associated with inflammation: (i) 
CD-36 interacts with toll-like receptors and Aβ inducing intracellular signaling and release of 
ROS, chemokines, and cytokines (Stewart, Stuart et al. 2010; Wilkinson and El Khoury 2012); 
(ii) FAT binds to thrombospondins producing inflammatory factors causing endothelial apoptosis 
(Cho 2012); (iii) CD-36 and advanced glycation-end products (RAGE) induce microglia 
activation  (Maillard-Lefebvre, Boulanger et al. 2009; Wilkinson and El Khoury 2012); (iv) CD-36 
interacts with fibrillar β-amyloid (fAβ)/integrins, inducing the expression of pro-inflammatory 
cytokines and chemokines  (Coraci, Husemann et al. 2002; Moore, El Khoury et al. 2002; El 
Khoury, Moore et al. 2003); and (v) CD-36 enhances macrophage and adipose tissue 
inflammation and impairs insulin signaling (Kennedy, Kuchibhotla et al. 2011). These studies 
suggest that CD-36 signaling pathways activated by different ligands mediate inflammatory 
responses in various metabolic and neurodegenerative disorders.   
Another interesting inflammatory pathway associated with CD-36 is the activation of 
NLRP3 inflammasome. This pathway is activated by the uptake of oxLDL by CD-36, resulting in 
the formation in the formation of intracellular cholesterol crystals that cause lysosomal 
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destabilization and NLRP3 activation (Sheedy, Grebe et al. 2013; Oury 2014). This CD36-
mediated inflammasome activation serves as evidence to link cholesterol build up to the chronic 
inflammatory process of atherosclerosis. In addition, other cells engage in further activating the 
NLRP3 inflammasome:  activated or injured endothelial cells, leukocytes and platelets release 
ATP, acting in a paracrine manner to transduce sterile inflammatory signals, such as P2X7 
receptor activation further contributing to  atherothrombosis (Sheedy, Grebe et al. 2013).  
Furthermore, recent publications suggest the inflammatory involvement of CD-36 in TBI 
(Cerecedo-Lopez, Kim-Lee et al. 2014), providing understanding of TBI neuroinflammation and 
as a potent therapeutic target for TBI treatment.  
 
3.1.3 Neuroinflammation in TBI Accompanied by CD-36 Expression in Brain and 
Spleen.  
We hypothesize that neuroinflammation via CD-36 has a temporal expression 
contributing to the pathology of TBI at the acute and chronic stages. As it does in ischemic 
injury, targeting CD-36 in the spleen and brain serves as a primary link between peripheral and 
central regulation of brain injury. The in vitro data presented in Chapter 2 strongly suggest CD-
36 upregulation in the brain and spleen immediately after injury   . At the completion of this Aim, 
we would gain a better understanding of the role of splenic CD-36 contributing to TBI 
neuroinflammation and if any corresponding alterations in inflammatory response exist in the 
brain (i.e., cortex and hippocampus). Based on reported data indicating that the spleen immune 
response contributes to the pathology observed in stroke animals, we envisioned a close 
interaction of CD-36 in spleen and brain in TBI as well. The critical timing (i.e., 24-48 hours) of 
CD-36 expression shift (from downregulation to upregulation) may signal the transition of 
functional effects of this immune response from pro-survival to pro-death.  This dynamic CD-36 
expression also suggests the therapeutic window for TBI.   
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3.2 Specific Materials and Methods  
Studies in Sprague-Dawley (SD) rats were carried out in accordance with the 
recommendation in the Guide for the Care and Use of Laboratory Animals of the National 
Institutes of Health. The protocol was approved by the Institutional Animal Care and Use 
Committee (IACUC) at the University of South Florida, College of Medicine. All male rats were 
housed under normal conditions (20°C, 50% relative humidity, and a 12-hou r light/dark cycle). 
A separate cohort of animals, the sham group, underwent the same experimental conditions 
and was also subjected to behavioral tests to assess motor function. Necessary precautions 
were taken to reduce pain and suffering of the animals throughout the study.  
 
3.2.1 Surgical Procedures 
Ten week old, male Sprague-Dawley rats (n=60) were subjected to mild TBI using the 
controlled cortical impact (CCI) injury model (Pittsburgh Precision Instruments, Inc, PA, USA). 
Animals were anesthetized using 1–2% isoflurane. Once deep anesthesia was achieved, 
individual animals were fixed in a stereotaxic frame (David Kopf Instruments, Tujunga, CA, 
USA), and anesthesia was maintained via gas mask. TBI injury surgeries consisted of animals 
subjected to scalp incision to expose the skull; using an electrical drill, a 4.0mm craniectomy 
was performed over the right frontoparietal cortex (2.0 mm anteroposterior (AP),+2.0 mm 
mediolateral (ML), and 1.0 mm dorsoventral (DV) to bregma (Paxinos G 2005; Glover, Tajiri et 
al. 2012). The pneumatically operated TBI device (with a convex tip diameter of 3.0 mm for rats) 
impacted the brain at a velocity of 6.0 m/s, reaching a depth of 1.0 mm for mild TBI, below the 
dura mater layer, and remained in the brain for 150 milliseconds (ms). The impactor rod was 
angled 15° degrees to the vertical to maintain a perpendicular position in reference to the 
tangential plane of the brain curvature at the impact surface (Yu, Kaneko et al. 2009). A linear 
variable displacement transducer (Macrosensors, Pennsauken, NJ) connected to the impactor 
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measured velocity and duration to verify consistency. This CCI approach produced skull fracture 
overlying the frontal cortex. All animals received the analgesic ketoprofen (5mg/kg of weight) 
post-operatively. Rats were monitored closely. Next, TBI animals and sham animals were 
grouped and sacrified at various post TBI time-points for future histological and protein analysis 
to determine CD-36 alterations.  
 
3.2.2 Immunohistochemistry of Brain  
Under deep anesthesia, rats were sacrificed at different time-points: 24 hours (hrs), 48 
hrs, 7 days, and 60 days post-TBI surgery, along with their corresponding sham groups. All 
animals underwent transcardial perfusion; rats were placed on their backs and blunt forceps 
were used to cut through the body cavity. The opening was extended laterally until reaching the 
rib cage. The rib cage was cut, and the sternum was lifted to expose the heart. The heart was 
held gently, and the needle was inserted ¼-inch into the left ventricle. The right atrium was cut 
using the irridectomy scissors. Through the ascending aorta, approximately 200 mL of ice cold 
phosphate buffer saline (PBS) followed by 200 mL of 4% paraformaldehyde (PFA) in phosphate 
buffer (PB) were used for brain perfusion. Sham animal groups underwent the same procedure. 
Brains and spleens were removed and post-fixed in the same fixative at 4°C for 24 hrs followed 
by two rounds of 30% sucrose in PB for 48 hrs. Brains were frozen at −24°C and mounted onto 
a 40 mm specimen disk using embedding medium. Coronal sectioning was carried out at a 
thickness of 30 µm by cryostat on every 6th (1/6) coronal section spanning the prefrontal cortex 
up to the entire dorsal hippocampus, starting at coordinates AP +2.70 mm and ending at AP-3.0 
mm relative to bregma. Coronal cryostat sections were stored in a cryoprotectant solution at –
20°C until immunohistochemical staining. 
 On day one, free-floating sections (30µm thickness) were incubated with mouse 
monoclonal anti-CD-36 (1:100, Abcam, USA), rabbit polyclonal anti MCP-1 (1:100, Abcam, 
USA) primary antibodies overnight at 4°C, followed by day two incubation with goat anti-mouse 
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secondary antibody (1:1000 Alexa 488, Molecular Probes, USA), and goat anti-rabbit secondary 
antibody 1:1000-2000 Alexa 594, Molecular Probes, USA) for 2 hrs at RT. Finally, tissue was 
incubated with Hoechst 33258 (bisBenzimideH 33258 trihydrochloride) for 30 mins (1:300 
Molecular Probes, USA) to visualize cell nuclei. Then tissue underwent three washes in PBS 
and was coverslipped with Fluoromount (Sigma). The same immunohistochemistry protocol 
described above was employed for all acute and chronic groups, with tissues incubated in 
mouse monoclonal anti-CD-36 (1:100, Abcam, USA) and rabbit polyclonal anti Iba-1 (1:300, 
WAKO, Japan) primary antibodies, followed by goat anti-mouse (1:1000 Alexa 488, Molecular 
Probes, USA) and goat anti-rabbit secondary antibodies (1:2000 Alexa 594, Molecular Probes, 
USA).   
Only sections from the 24-hrs group underwent IHC; initial preliminary staining showed 
CD-36 predominantly on the brain cortex of acute groups primarily and scarcely on the 60-day 
chronic group. Sections were stained with mouse monoclonal anti-CD-36 (1:100, Abcam, USA) 
and rabbit monoclonal anti-NeuN (1:500, Millipore, USA) primary antibodies overnight at 4°C. 
The next day, tissue was incubated for 2 hrs in goat anti-mouse secondary antibody (1:1000 
Alexa 488, Molecular Probes, USA) and goat anti-rabbit secondary antibody (1:1000-2000 
Alexa 594, Molecular Probes, USA), followed by incubation with Hoechst (bisBenzimideH 33258 
trihydrochloride) for 30 mins (1:300 Molecular Probes, USA), then tissue underwent three 
washes in PBS for 30 mins and was coverslipped with Fluoromount (Sigma). Likewise, only 
sections from the 24-hrs group went through the same incubation steps with mouse monoclonal 
anti-CD-36 (1:100, Abcam, USA) and rabbit polyclonal anti-GFAP (1:2000,DAKO, USA) primary 
antibodies, with goat anti-mouse (1:1000 Alexa 488, Molecular Probes, USA) and goat anti-
rabbit secondary antibodies (1:1000-2000 Alexa 594, Molecular Probes, USA). 
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3.2.3 Immunohistochemistry of Spleen 
Spleen cryosectioning was carried out at a thickness of 20 µm by cryostat at -19°C. 
Fluorescent immunostaining was done on every 6th (1/6) coronal section and mounted directly 
onto the slide. Day one involved incubating tissue sections with mouse monoclonal anti-CD-36 
(1:100, Abcam, USA) overnight. The next day, tissue slides were incubated in goat anti-mouse 
secondary antibody for 2 hrs (1:1000 Alexa 488, Molecular Probes, USA). Then tissue was 
washed 3 times for 10 mins and coverslipped with DAPI H-1200 mounting medium 
(Vectashield). IHC was performed on spleen sections of acute and chronic TBI groups and their 
respective controls.   
A multiphoton laser confocal scanning microscope (FV1000 MPE, Olympus, USA) was 
used for observation and imaging for all immunofluorescence photomicrographs of the motor 
cortex area (M1, M2) at a 40x magnification; only linear adjustments (brightness and contrast) 
were made to the figures. When quantification of percentage of positive cells was determined, Z 
stacks were created at 1 µm intervals throughout the 30 µm of the sections with a guard region 
of 2 mm excluded from top and bottom of the Z stack. The Z stacks were rotated in all planes to 
verify double labeling. A fluorescent microscope (Axio Imager.Z1, Zeiss, USA) was used for 
observation and imaging of spleen slides at a 40x magnification. Six serial spleen coronal 
sections were quantified using Image J and results are displayed as the average mean of 
fluorescent intensity. 
 
3.2.4 Statistical analysis on indirect immunofluorescence in brain 
 CD-36, MCP-1, Iba-1, Hoechst positive cells adjacent to impact area (M1 motor cortex 
area) were counted using Image J using 6 serial coronal sections. Results showed the average 
mean of the cell ratios of CD-36/DAPI, (CD-36 + MCP-1 cells)/ total MCP-1, MCP-1/DAPI, CD-
36/DAPI, Iba-1/DAPI, CD-36/Iba-1. Likewise, the contralateral side of injured brains and sham 
brains were analyzed. Explored coronal sections correspond to +2.7 to -0.3 mm with respect to 
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bregma. The data obtained were analyzed using the Graph Pad Prism 5.0 software and were 
evaluated statistically using one-way analysis of variance (ANOVA) for group comparisons with 
95% CI followed by subsequent pair-wise comparisons using post hoc Bonferonni test. All data 
are presented as mean values ± SEM. Statistical significance was set at p<0.05 for all analyses. 
Likewise for the 24-hrs group CD-36, NeuN, GFAP, and Hoechst positive cells adjacent to 
impact area (M1 motor cortex area) were counted using Image J using 6 serial coronal sections. 
Results showed the average mean of the cell ratios of CD-36/DAPI, (CD-36 + NeuN cells)/ total 
NeuN cells, (CD-36 + GFAP cells)/ total GFAP cells. In this case, the contralateral side and the 
control brains (non-TBI/naïve brains) were compared against the ipsilateral side. Coronal 
sections correspond to +2.7 to -0.3 mm with respect to bregma. The data obtained was also  
analyzed using the Graph Pad Prism 5.0 software and were evaluated statistically using one-
way analysis of variance (ANOVA) for group comparisons with 95% CI, followed by subsequent 
pair-wise comparisons using post hoc Bonferonni test. All data are presented as mean values ± 
SEM. Statistical significance was set at p<0.05 for all analyses. 
 
3.2.5 Statistical analysis on fluorescence intensity in spleen 
The data obtained was analyzed using the Graph Pad Prism 5.0 software to run the 
unpaired t-test with Welch’s correction to compare spleen from TBI animals vs. sham animals. 
 
3.2.6 Western Blot 
A second set of animals were sacrificed at different time-points under deep anesthesia: 
24-hrs, 48-hrs, and 7 days post-TBI surgery, along with their corresponding sham groups. All 
TBI animals and shams underwent transcardial perfusion as previously mentioned. Brain tissue 
was dissected into right and left brain regions for the cortex, striatum, dorsal and ventral 
hippocampus (Chiu, Lau et al. 2007). Immediately, tissues and spleens were placed in 
individual cryoprotectant vials in liquid nitrogen (-196°C) and transferred to a -80°C freezer. 
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Tissue from the cortex and spleen were homogenized using an electric tissue homogenizer in 
1:10 weight to volume ratio of ice-cold RIPA buffer (Cell Signaling Technology, USA) containing 
1% protease inhibitor cocktail (Sigma-Aldrich, USA). Following homogenization, sample lysates 
were centrifuged at 10,000rpm at 4ºC for two rounds of 30 mins. Pellets were discarded, and 
the supernatant was then aliquoted in 50μl samples and stored at -80°C. Next, a protein assay 
(BCA Protein Assay, Pierce, USA) was applied to determine total protein concentration for each 
fraction sample. Pre-cast electrophoresis gels (4-15% Mini Protean TGX, Bio-Rad, USA) were 
loaded with 30μg of total protein per sample per well and current was applied at 70V for 45 
mins, resuming at 100V for 30min. Proteins were transferred to nitrocellulose membranes (Bio-
Rad, USA) using a Criterion blotter (Bio-Rad, USA), at 100V, for 30 mins. The membranes were 
pre-incubated in 5% non-fat dairy milk (NFDM)/Phosphate Buffered Saline (PBS, Pierce, 
USA)/0.05% Tween 20 (PBST, Fisher-Scientific, USA) for 1 hr, then incubated overnight at 4°C 
with one of the following primary antibodies: rabbit monoclonal CD-36 (1:250, Abcam, USA); 
mouse monoclonal GAPDH (1:25,000). The next day, membranes were washed with PBST and 
incubated with the corresponding secondary antibody): goat anti-rabbit IR Dye 800 (1:3000, 
LICOR, USA) and goat anti mouse 680 (1:25,000, LICOR, USA) during 2 hrs at RT. The 
membranes were thoroughly washed with PBST and placed into an Odyssey infrared imager 
(LICOR, USA) for band detection. Images were analyzed through the Image Studio software 
(LICOR, USA) for band density measurements. The band density ratios from TBI vs. sham 
groups were statistically compared. 
 
3.2.7 Statistical Analysis on Western Blot 
The data were evaluated statistically using one way analysis of variance (ANOVA) for 
group comparisons with 95% CI followed by subsequent pair wise comparisons using the post 
hoc Bonferonni test. All data are presented as mean values ± SEM. Statistical significance was 
set at p<0.05 for all analyses. 
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3.3 Results  
 
3.3.1 CD-36 Expression in the TBI Brain 
Histological experiments of acute time-points post-TBI revealed that at the acute stage 
CD-36, expression was found predominantly in the M1 and M2 cortical regions, along the 
cingulate cortex of the ipsilateral frontal lobe of the brain. CD-36 expression also extended to 
the cingulate cortex of contralateral brain hemisphere (Figures 2-4). These results suggest that 
at acute stages the CD-36 inflammatory response disseminates from the core of impact to the 
rest of the motor cortex reaching the contralateral side of the brain.  We correlated these 
findings with other neuroinflammatory markers such as MCP-1 and Iba-1 for microglia.  
We found MCP-1 positive expressing cells with two distinct morphologies: star-shaped 
cells and other cells that also co-localized with CD-36.  MCP-1 is typically expressed by 
monocytes and vascular endothelial cells, among others in culture. MCP-1 is a chemokine, a 
mediator of a number of processes: it regulates migration and infiltration of 
monocytes/macrophages, immune response surveillance of tissues, and in the response to 
inflammation, wound healing, and in general systemic reactions following tissue or organ 
injuries (Deshmane, Kremlev et al. 2009). About 5% of cells show co-localization of CD-36 & 
MCP-1. In the case of the sham acute groups at different time-points, they showed very few CD-
36+ expressing cells (<5%) compared to TBI. Thus, an up regulation of CD-36 expression 
suggests its pathological role in TBI. Results on the animal group corresponding to the 60 day 
time-point after TBI revealed scarce immunoreactivity for CD-36 in the area of impact and none 
in the hippocampal or striatum areas (Figure 5). We observed brain co-localization of CD-36, 
MCP-1 and Iba-1 on impact cortical area, significant increases of CD-36 and MCP-1 positive 
cells in the ipsi vs. contra hemispheres of TBI vs. sham groups, but no significant increases of 
Iba-1 expressing cells over time. Immunoblotting support overexpression of CD-36 in brain at 
acute post-TBI time-points vs. sham. Next, we wanted to know if CD-36 imparted neuronal or 
56 
astrocytic-mediated inflammation in one of the acute groups, the 24-hrs post-TBI. Thus, we 
tested CD-36 with well-known neuronal and astrocytic markers. We found CD-36 and NeuN co-
localization in neurons in the impact area in this acute stage of TBI (Figure 6 A-D). 
 
 
 
Figure 2. Co-localization of CD-36/MCP-1, CD-36/Iba-1 at the cortical core of impact at 24 
hours post-TBI. Fluorescence photomicrographs revealed co-localization of CD-36 & MCP-1, 
CD-36 and Iba-1 at the cortical core of impact at 24 hrs among the TBI (n=4) and sham groups 
(n=3). Direct quantification of CD-36 positive (+) cells in the vicinity also expressed MCP-1 
along the cingulate cortex (CC) of the ipsilateral (ipsi) and contralateral (contra) sides. For the 
CD-36/MCP-1 stain one way ANOVA testing showed statistical significance when comparing 
the ipsi vs. contra and sham group CD-36/DAPI, (CD-36+/MCP-1)/MCP-1, and MCP-1/DAPI 
ratios. Their F values were (F (2,8) = 17.26, p < .005),  (F(2,8) = 20.35, p < .0005),  F (2,8) = 
26.65, p < .0005), respectively. For the CD-36/Iba-1 stain one way ANOVA testing showed 
statistical significance when comparing the ipsi vs. contra and sham group CD-36/DAPI ratios 
(F(2,8) = 65.10, p < .0005).  The comparison of the CD-36/Iba-1 ratio between the ipsi and 
sham groups showed significance F (2,8) =11.31, p < .005). The comparison of the Iba-1/DAPI 
ratio among the three groups was not significant.  Fluorescence photomicrographs were taken 
at a 40x magnification. 
57 
 
 
 
Figure 3. Co-localization of CD-36/MCP-1, CD-36/Iba-1 at the cortical core of impact at 48 
hours post-TBI. Fluorescence photomicrographs revealed co-localization of CD-36 & MCP-1, 
CD-36/Iba-1 at the cortical core of impact at 48 hrs among the TBI (n=4) and sham groups 
(n=3). Direct quantification of CD-36 positive (+) cells in the vicinity also expressed MCP-1 
along the cingulate cortex (CC) of the ipsilateral (ipsi) and contralateral (contra) sides. For the 
CD-36/MCP-1 stain one way ANOVA testing showed statistical significance when comparing 
the ipsi vs. contra and sham group CD-36/DAPI, (CD-36+/MCP-1)/MCP-1, and MCP-1/DAPI 
ratios. Their F values were (F (2,8) = 33.55, p < .005),  (F (2,8) = 9.618, p < .05).  F (2,8) = 
53.11, p < .0005), respectively. For the CD-36/Iba-1 stain one way ANOVA testing showed 
statistical significance when comparing the ipsi vs. contra and sham CD-36/DAPI ratios (F(2,8) 
=74.76, p < .0005).  The comparison of the CD-36/Iba-1 ratio between the sham group vs. ipsi 
and contra showed significance F (2,8) =10.27, p < .005). The comparison of the Iba-1/DAPI 
ratio among the three groups was not significant.  Fluorescence photomicrographs were taken 
at a 40x magnification. 
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Figure 4. Co-localization of CD-36/MCP-1, CD-36/Iba-1 at the cortical core of impact at 7 
days post-TBI. Fluorescence photomicrographs revealed co-localization of CD-36 & MCP-1, 
CD-36/Iba-1 at the cortical core of impact at 48 hrs among the TBI (n=4) and sham groups 
(n=3). Direct quantification of CD-36 positive (+) cells in the vicinity also expressed MCP-1 
along the cingulate cortex (CC) of the ipsilateral (ipsi) and contralateral (contra) sides. For the 
CD-36/MCP-1 stain one way ANOVA testing showed statistical significance when comparing 
the ipsi vs. contra and sham group ratios of CD-36/DAPI, (CD-36+/MCP-1)/MCP-1, and MCP-
1/DAPI. Their F values were (F (2,8) = 27.31, p < .0005),  (F(2,8) = 13.01, p < .005), F(2,8) = 
15.23, p < .005), respectively. For the CD-36/Iba-1 stain one way ANOVA testing showed 
statistical significance when comparing sham vs. ipsi  and contra CD-36/DAPI ratios (F(2,8) 
=23.11, p < .0005).  The comparison of the CD-36/Iba-1 ratio between the sham group vs. ipsi 
and contra showed significance F (2,8) =26, p < .0005). There was a significant difference in the 
Iba-1/DAPI ratio of the ipsilateral vs. contra and sham.  Fluorescence photomicrographs were 
taken at a 40x magnification. 
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Figure 5. Co-localization of CD-36/MCP-1, CD-36/Iba-1 at the cortical core of impact at 60 
days post-TBI. Fluorescence photomicrographs showed immunodetection at the cortical core 
of impact at 60 days Post-TBI. No statistical significance was present when comparing the 
average cell ratios, CD-36/DAPI, (CD-36 + MCP-1/MCP-1), and MCP-1/DAPI among the 
ipsilateral, contralateral & sham groups. No statistical significance was present when comparing 
the average cell ratios of CD-36/DAPI and CD-36/Iba-1,There was a small significant difference 
in the  Iba-1/DAPI ratio of the sham vs. contra and ipsi groups F(2,8) =198.6, p < 0.0005). 
Fluorescence photomicrographs were taken at a 40x magnification. 
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Figure 6. A-D Co-localization of CD-36/NeuN at 24 hours after TBI. Fluorescence 
photomicrographs revealed co-localization of CD-36 with NeuN found only in the ipsilateral (A) 
hemisphere demonstrates that neuronal expression of CD-36 follows 24 hrs after TBI (n=4). No 
co-localization is shown in the (B) contralateral (n=4), and (C) non-TBI hemispheres (n=3). Z-
stacked (D) Image shows co-labeling of both markers at a magnification of 100x. The data 
obtained were evaluated statistically using one way analysis of variance (ANOVA) for group 
comparisons with 95% CI followed by subsequent pair wise comparisons using post hoc 
Bonferonni test (F(2,8)=16.14, p < .005). All data are presented as mean values ±SEM. 
Statistical significance was set at p<0.05 for all analyses. 
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These results provide evidence of CD-36 mediated inflammation in neurons. We also 
found minimal co-localization of CD-36 with GFAP, which could indicate a partial CD-36 
mediated inflammation in astrocytes (Figure 7 A-D). Nevertheless, we observed widespread 
astrogliosis throughout the injured hemisphere, including the cortex, corpus callosum, and 
hippocampus. GFAP immunoreactivity was also observed in the contralateral hemisphere but to 
a lesser extent when compared to the ipsilateral hemisphere. Yet active astrocytes were found 
to be widespread also in the cortex, corpus callosum, and hippocampus of the left hemisphere.  
We did not perform the double stain on the chronic group since the initial single CD-36 stain 
showed negative/minimal immunoreactivity. Accordingly, we limited this study to the acute 
stage.  
 
3.3.2 CD-36 in the TBI Spleen 
Recent ischemic and hyperlipidemic rodent models suggest that infiltrating 
monocytes/macrophages from the periphery are the major source of CD-36 in the post-ischemic 
brain. Accordingly, we characterized the spleen pathological alterations in the acute and chronic 
stages of TBI by indirect immunofluorescence and quantification of fluorescence intensity of CD-
36 positive monocytes. We observed that CD-36 positive monocytes localized mostly in the red 
pulp as opposed to their scarce expression in the white pulp. The increased CD-36 expression 
in spleen suggests that the splenic inflammatory response via the CD-36 pathway may 
contribute to the general inflammatory response after TBI (Figures 8-11). 
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Figure 7. A-D Minimal Co-localization of CD-36/GFAP at 24 hours after TBI. Fluorescence 
photomicrographs showed minimal co-localization of CD-36 with GFAP found in the ipisilateral 
hemisphere (A). No co-localization is shown in the contralateral (n=3) (B) and non-TBI (n=4) 
(C). Z-stacked (D) image shows co-localization of both markers in the injured motor cortex at a 
magnification of 100x. The data obtained were evaluated statistically using one way analysis of 
variance (ANOVA) for group comparisons with 95% CI followed by subsequent pair wise 
comparisons using post hoc Bonferonni test (F(2,8)=20, p<0.05). All data are presented as 
mean values ±SEM. Statistical significance was set at p<0.05 for all analyses.  
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Figure 8. Spleen CD-36 Immunodetection at 24 hours post-TBI. Fluorescence 
photomicrographs demonstrate CD-36 positive (+) monocytes predominate in the vicinity/ 
borderline of the red and white pulp in the 24-hrs TBI spleen (1A) compared to 24-hrs sham 
spleen (1B). Scale bar = 50um. Fluorescence intensity of CD-36 positive (+) cells was increased 
in the spleen of TBI animals (n=3) vs. sham group (n=3). Photomicrographs were taken at a 
magnification of 40x. The data obtained showed no significance between the two groups, data 
was analyzed using the graph pad Prism 5.0 software to run the unpaired t-test with Welch’s 
correction (t=0.3613, df=4). 
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Figure 9. Spleen CD-36 immunodetection at 48 hours post TBI. Fluorescence 
photomicrographs revealed CD-36 positive (+) monocytes predominate in the vicinity/ borderline 
of the red and white pulp in the 48-hrs TBI spleen (2A) compared to the 48-hrs sham spleen 
(2B). Scale bar = 50um. Fluorescence intensity of CD-36 postive (+) cells showed an increased 
difference between TBI (n=3) and sham groups (n=4). Asterisk (*) denotes significance t 
=1.038, df = 5. Unpaired t-test with Welch’s correction. Photomicrographs were taken at a 
magnification of 40x. The data obtained was analyzed using the graph pad Prism 5.0 software 
to run the unpaired t-test with Welch’s correction.   
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Figure 10. Spleen CD-36 immunodetection at 7 days post TBI. Fluorescence 
photomicrographs showed CD-36 positive (+) monocytes do not show an larger expression in 
the vicinity/borderline of the red and white pulp in the 7-days TBI spleen (3A) compared to 7-
days sham spleen (3B). Scale bar = 50um. Fluorescence intensity of CD-36 positive (+) cells in 
7 day TBI group (n=3) does not show difference from sham groups (n=4). Photomicrographs 
were taken at a magnification of 40x. The data obtained was analyzed using the graph pad 
Prism 5.0 software to run the unpaired t-test with Welch’s correction (t=0.3010, df=5). 
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Figure 11. Spleen CD-36 immunodetection at 60 days post TBI. Fluorescence 
photomicrographs demonstrated CD-36 positive (+) monocytes predominate in the vicinity/ 
borderline of the red and white pulp in the 60-days TBI spleen (4A) compared to the 60-days 
sham spleen (4B). Scale bar = 50um. Fluorescence intensity of CD-36 postive (+) cells was 
increased in the spleen of TBI animals (n=3) vs. sham group (n=6). Asterisk (*) denotes 
significance ( t = 2.386, df = 4). The data obtained was analyzed using the graph pad Prism 5.0 
software to run the unpaired t-test with Welch’s correction.  Photomicrographs were taken at a 
magnification of 40x. 
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3.3.3 Western Blot 
 
3.3.3.1 Protein Detection in the Brain Cortex 
To further detect the presence of CD-36 in the area of impacted brain (i.e., cortex), we 
used Western blot to measure and compare semi-quantitatively protein levels between brain 
cortical extracts of sham and acute TBI groups. Protein separation is based on charge and 
molecular weight size (MW). Despite being a useful technique, it has its limitations, since it does 
not measure the absolute value of protein, but instead the amount of protein relative to others of 
known MW. Western blot analysis of CD-36 protein expression was detected in the brain cortex 
of TBI and sham animals. GAPDH was used as normalizing protein. Protein density bands were 
detected at 78 kDa, the glycosylated CD-36 fragment. The ratio between the band density for 
CD-36 vs. GAPDH showed a significant increase in CD-36 protein levels in the ipsilateral brain 
cortex of the 24-hrs and 48-hrs post TBI groups vs. the contralateral brain cortex fractions, and 
also against their corresponding sham groups (Figures 12-13).  Western blot analysis of CD-36 
protein expression of TBI and sham animals in the spleen showed no significant difference 
among groups. Bands were detected at 53 kDa, the non-glycosylated CD-36 fragment.  
 
3.3.3.2 Protein Detection in the Spleen 
We decided to probe for protein levels in the spleen since it is implicated in the 
inflammatory response after TBI, as documented by previous publications in stroke and our 
recent findings from whole spleen lysates in the CD-36 neonatal TBI studies. Based on our IHC 
results CD-36 positive monocytes in the spleen post-TBI suggest their role in the peripheral 
immune response. Thus, we wanted to compare CD-36 splenic protein levels in TBI vs. sham 
groups. Our results detected CD-36 in spleen lysates of TBI and sham groups. The relative 
protein ratios of the 53 kDa fragment of CD-36 in TBI vs. sham showed no significant difference 
relative to GAPDH. 
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Figure 12. CD-36 brain cortex protein expression at 24  post-TBI. Two bands were 
detected, a band detected at 78 kDa, glycosylated CD-36 fragment, and the second band at 53 
kDa, non-glycosylated fragment. We measure band density for the 78kDa glycosylated fragment 
and compared it against GAPDH. The data obtained were evaluated statistically using one way 
analysis of variance (ANOVA) for group comparisons (F(2,8)=6.477, p < 0.05), followed by 
subsequent pair wise comparisons using post hoc Bonferonni test .  Significance (p<0.05) was  
observed in the indicated graph columns for the 24Hrs post TBI  group GAPDH was used as 
normalizing protein. Sample size for the TBI group (n=4) and Sham groups (n=3). 
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Figure 13. CD-36 brain protein expression 48 hours post-TBI. Two bands were detected, a 
band detected at 78 kDa, glycosylated CD-36 fragment, and the second band at 53 kDa, non-
glycosylated fragment. We measure band density for the 78kDa glycosylated fragment and 
compared it against GAPDH. The data obtained were evaluated statistically using one way 
analysis of variance (ANOVA) for group comparisons, (F(2,8)=4.756, p < 0.05) followed by 
subsequent pair wise comparisons using post hoc Bonferonni test .  Significance (p<0.05) was  
observed in the indicated graph columns for the 24Hrs post TBI  group GAPDH was used as 
normalizing protein. Sample size for the TBI group (n=4) and Sham groups (n=3). 
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Figure 14.  CD-36 protein expression in spleen 24 hours post-TBI. A band detected at 
53kDa, the non–glycosylated CD-36 fragment.  No significance was observed in the indicated 
graph columns for the 24Hrs post TBI group. ). The data obtained was analyzed using the graph 
pad Prism 5.0 software to run the unpaired t-test with Welch’s correction (t=0.5313, df=5) 
Sample size for the TBI group (n=4) and Sham groups (n=3).GAPDH was used as a 
normalizing protein. 
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Figure 15.  CD-36 protein expression in spleen of 48 hours post-TBI. A band detected at 
53kDa, the non–glycosylated CD-36 fragment. No significance was observed in the indicated 
graph columns for the 48Hrs post TBI group. The data obtained was analyzed using the graph 
pad Prism 5.0 software to run the unpaired t-test with Welch’s correction (t=0.5121, df=3) 
Sample size for the TBI group (n=3) and Sham groups (n=3). GAPDH was used as normalizing 
protein.  
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Figure 16. CD-36 protein expression in spleen of 7 days post-TBI.  A band was detected at 
53kDa, the non–glycosylated CD-36 fragment. No significance was observed in the indicated 
graph columns for the 7 Days post TBI group. The data obtained was analyzed using the graph 
pad Prism 5.0 software to run the unpaired t-test with Welch’s correction (t=1.292, df=3) Sample 
size for the TBI group (n=3) and Sham groups (n=3). GAPDH was used as normalizing protein. 
 
However, CD-36 protein ratio levels were slightly increased in the 24-hrs compared to 
the 48-hrs and 7 day groups (Figures14-16). This suggests an elevated CD-36 inflammatory 
splenic response early after TBI. 
 
3.4 Discussion 
In this study we examined the relevance of CD-36 to post-traumatic inflammation that 
accompanies the secondary brain damage associated with TBI. We showed a novel observation 
of increased CD-36 positive cell populations in the brain of TBI animals that appeared to peak 
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during the early phase of injury, with CD-36 elevation maintained up to 7 days post-TBI, an 
indication for CD-36’s role in acute neuroinflammation. Along with the production of other 
inflammatory mediators, including MCP-1 and Iba-1, CD-36 cell immunoreactivity was robustly 
upregulated in the area of impacted brain in acute time-points over that of the chronic TBI 
period.  
The non-detectable expression of CD-36 in brain cortical regions at the 60-day group 
suggests a decline in the CD-36 involvement in the progressive inflammation seen in chronic 
TBI. The observed dynamic CD-36 expression in the acute phase of TBI suggests a therapeutic 
window for TBI within the first 24 hours when targeting CD-36-mediated neuroinflammation. In 
addition, another interesting observation is the co-localization of CD-36 with NeuN, indicating a 
direct influence of CD-36 in mediating inflammation, and likely cell death, in neurons in the 
cortex. In contrast, minimal co-localization of CD-36 with GFAP suggests that CD-36 minimally 
contributes to astrocytic-mediated inflammation. Interestingly, TBI-exposed MCP-1 knockout 
mice showed no co-localization of MCP-1 with NeuN and GFAP in the cortex within 4 days of 
TBI; instead, there was co-localization of MCP-1 with a subset of F4/80-positive amoeboid 
macrophages accumulating in the lesion site (Semple, Bye et al. 2010). Further studies are 
necessary to further characterize the cell phenotypes affected by CD-36 over-expression, which 
should lead to a better understanding of the CD-36-mediate inflammation and its treatment. 
Neuroinflammation involves a cascade of events contributing to progressive damage. 
Our present data suggest a solid connection between CD-36 and MCP-1 after TBI. The 
chemokine MCP-1 is implicated in macrophage recruitment into damaged parenchyma after 
TBI.  Consistent with CD-36 induction, previous work by our laboratory has established 
increased CD-36 protein expression in the brain and spleen of TBI-exposed neo-natal rats. 
Here, we further investigated CD-36 protein expression specifically in the brain cortex of acute 
and chronic groups. CD-36 protein levels were abundant in the ipsilateral brain cortex relative to 
contralateral and sham samples. In addition, we determined a critical timing (i.e., 24-48 hours, 
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and 7 days) of CD-36 expression (from downregulation to upregulation) in the brain, which may 
signal the transition of functional effects of this immune response from pro-survival to cell death. 
The overall decline of CD-36 expression across the acute groups and the 60 day post TBI group 
might be a delayed response of hematogenous macrophages to arrive at the site of injury. For 
example, in a stroke study mononuclear phagocytes accumulated in the injured brain are initially 
resident microglia at 3 to 4 days, and blood-derived macrophages at 6 to 7 days (Schroeter, 
Jander et al. 1997). This explains brain levels, but does not explain CD-36 downregulation in the 
spleen at 48 hours and 7 days. 
 Our study also examined CD-36 protein expression levels in the spleen during acute TBI 
time- points. No significant differences in protein levels occurred between TBI and sham 
animals at each time-point, but in the initial 24 hrs after TBI, CD-36 protein levels were slightly 
higher than those in the 48-hrs and 7 days groups. Although a CD-36 peak splenic expression 
occurred mainly at 24 hrs in the TBI, there was no significant difference between TBI and sham 
groups, yet the relative protein expression is higher at 24 hrs when compared to the 48-hrs TBI 
group. However, there was no significant difference when comparing TBI vs sham at 48 hrs and 
7 days post-TBI. We assume this initial splenic response peaking within the first 24 hrs is CD-36 
mediated, followed by a slow decline afterwards. In our study, we were limited by a small 
number of animals to account for CD-36 expression in the spleen; this may be a reason why we 
observed no difference. If we increase sample size, we may be able to detect a significant 
increase in CD-36 protein expression among the acute and sham groups. Yet, there are cellular 
evens and molecular interactions of CD-36 with pro-inflammatory and anti-inflammatory 
cytokines/chemokines that may also be responsible for CD-36 downregulation in the spleen. 
 Recent studies support upregulation of CD-36 in brain and plasma of mice early after 
TBI (Doyle and Buckwalter 2012; Kim, Febbraio et al. 2012), MCP-1 levels in human CSF 
(Semple, Bye et al. 2010), and in serum of rats exposed to experimental TBI within hours of 
injury (Rancan, Otto et al. 2001; Rhodes, Sharkey et al. 2009; Semple, Bye et al. 2010). This 
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may indicate an initial CSF chemokine production as part of the initial responses to TBI, 
triggering subsequent neuroinflammatory cascades. The detection of these inflammatory 
mediators in serum and plasma of TBI patients and TBI rodents opens up new avenues for 
clinical translation of CD-36 as a screening biomarker.  
 An important phenomenon is monocyte trafficking to the site of injury. Monocyte 
recruitment is depicted as a tightly regulated event involving a steady paced influx of various 
monocyte subsets that either express or do not express the pro-inflammatory chemokine 
receptor CCR2 (Hughes, Allegrini et al. 2002; Babcock, Kuziel et al. 2003; Dimitrijevic, 
Stamatovic et al. 2007). A possible explanation for the CD-36 protein downregulation in the 
spleen of acute time-points after the initial 24 hrs boost may be that different subsets of 
monocytes are activated by other inflammatory signaling pathways over those CD-36 mediated 
monocytes subsets. A study found temporal differences in peripheral immunity after TBI in a 
murine model of closed head injury at early time-points (1-7 days) and later ones (30 days and 
60 days) after injury. The study’s relevant findings include a loss of thymocytes as early as 3 
days after injury; a reduction in  blood monocyte counts as early as 24 hrs after injury in TBI vs. 
sham groups, a response that was sustained during the next 30 days after injury; and at 60 
days post-TBI, the researchers detected a shift in the monocyte make-up towards an anti-
inflammatory (M2) phenotype (Schwulst, Trahanas et al. 2013). 
 A second specific connection between CD-36 and pro-inflammatory chemokines occurs 
between CD-36 and the chemokine receptor CCR2, activated by the MCP-1 chemokine. For 
instance CD-36 ligands induced CC and CXC chemokine production in stroke, and the 
increases were attenuated in CD-36 deficient mice (Kim, Gautam et al. 1995; Moore, El Khoury 
et al. 2002; Stewart, Stuart et al. 2010). In addition, previous reports linked the spleen to stroke 
pathology; the larger the injury associated with hyperlipidemia, the greater the reduction in 
spleen weight, and the higher the expression of CCR2 in the post-ischemic brain (Schober, 
Zernecke et al. 2004). Overall, these studies suggest various subsets of monocytes traveling 
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from the spleen to the area of injury. The range of monocyte subsets becoming activated after 
injury, such as in stroke and TBI, may include other non CD-36 related inflammatory signaling 
pathways. 
 In this project, we showed that CD-36 is elevated 24 hours after TBI, and even after 7 
days post-TBI in the brain cortex. We have demonstrated that CD-36 is significantly elevated in 
the brain cortex of acute TBI time points when compared to contralateral and sham animals. 
Our findings support the upregulation of brain and splenic CD-36 mediated activation in the first 
24 hours after TBI. Yet the mounted CD-36 brain response is sustained until 7 days post-TBI. In 
contrast, splenic CD-36 expression remains unchanged even after days of injury, but it declines 
after 1 day. The expression of CD-36 with the studied inflammatory markers, such as MCP-1 
and Iba-1, suggests macrophage activation, certain/minimal astrocyte activation in the brain 
cortex, and microglia activation associated to other inflammatory mechanisms after TBI. In the 
case of the 60-Day post TBI group, very few cells express CD-36 in the cortex (and spleen), 
suggesting that CD-36 has a minimal role in chronic inflammation, but is more prominent in the 
acute stages of TBI. 
 Future directions in the study of CD-36 as an inflammatory mediator may expand on how 
CD-36 regulates the mobilization of various monocyte subset populations by interacting with 
other pro-inflammatory cytokines/chemokines and their receptors, such as CCR2. As described 
by murine and human studies of inflammatory and cardiovascular diseases, monocytes possess 
the ability to differentiate into inflammatory or anti-inflammatory subsets whenever they sense 
environmental changes (Ingersoll, Platt et al. 2011; Yang, Zhang et al. 2014).  This ability of 
heterogeneity in monocyte subsets may serve valuable in predicting the outcome of TBI-related 
inflammation. Current studies are focusing on defining the inflammatory and anti-inflammatory 
functional phenotypes of human monocyte subsets. It will be interesting to identify temporal 
profiles of cytokines/chemokines influencing monocyte subsets in the brain and spleen of TBI 
animal models, and at the same time compare them to groups of animals subjected to 
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splenectomy, as these observations may provide further insights on the inflammation-mediated 
pathology and treatment of TBI. We also suggest focusing on those monocyte subsets that 
infiltrate within hours after injury up to 7 days. This temporal phenomena of monocyte infiltration 
has been described in stroke murine studies (Gelderblom, Leypoldt et al. 2009; Jin, Yang et al. 
2010). Thus, in vitro studies may be conducted to block CD-36 and record any differences on 
monocyte subsets, their ability to acquire a particular phenotype in circulation, and their 
peripheral influence after injury.  
  There are also pharmacological approaches using specific CD-36 inhibitor, which would 
contribute allow a much better understanding of CD-36 target engagement effects. We also 
recognized that the major limitation in this study included small sample size, which likely 
affected the statistical analyses of CD-36 protein expression. Alternatively, the lack of alteration 
in CD-36 expression may be due to a rapid upregulation or decline associated with the supra-
acute period post-TBI not captured in this study. Nonetheless, these results demonstrated that 
CD-36 closely accompanied the inflammation in the acute TBI period (24 hours to 7 days).  
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CHAPTER 4 
PHARMACOLOGICAL INTERVENTIONS DESIGNED TO ABROGATE SECONDARY 
INFLAMMATION AFTER TBI INJURY   
 
4.1. Introduction. 
 Stroke murine animal models have shown that reducing CD-36 mediated inflammation 
may be a useful therapeutic strategy to diminish vascular injury, glial scar formation, and cell 
death (Bao, Qin et al. 2012; Cho 2012; Doyle and Buckwalter 2012). Recent human studies 
support sRAGE as a candidate in the prognosis and follow up after ischemic and hemorrhagic 
stroke (Qian, Ding et al. 2012; Menini, Ikeda et al. 2013; Tang, Wang et al. 2013). These studies 
reveal: a) ischemic and hemorrhagic stroke patients have an increase in sRAGE serum levels 
days after stroke (ranging between 26%-296%, p<0.001), and this change paralleled recovery 
and recurrence or aggravation of the episodes (Menini, Ikeda et al. 2013); b)  acute ischemic 
stroke patients and mice, and primary cortical neurons subjected to oxygen and glucose 
deprivation showed increased sRAGE plasma levels within 48hours of injury; furthermore, 
sRAGE recombinant administration (intravenously) was effective in reduction of infiltrating 
immune cells, improving the outcome of injury in mice, and protecting cultured neurons against 
hypoxia and cell death (Tang, Wang et al. 2013). In addition, in vivo and in vitro studies indicate 
that the down-regulation of CD-36 by novel class antioxidant peptides may be a useful strategy 
to treat ischemic stroke victims (Cho, Szeto et al. 2007).  A series of pilot studies performed by 
colleagues demonstrated the inhibitory action of sRAGE, soluble receptor of advanced glycation 
end products, for the CD-36 receptor in various cell types (Chapter 1, Figure 2). Data revealed 
sRAGE inhibitory activity on cell association of HOCl-LDL to:  a) stably transfected Chinese 
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hamster ovary (CHO) cells expressing murine scavenger receptor class B, type I (SR-BI, termed 
CHO-SR-BI), human CD-36 (termed CHO-CD-36); b) and most importantly to human spleen-
derived monocytes/macrophages (MD cells). Additionally, this team tested in an in vivo model of 
neonatal rat TBI the ability of sRAGE to alter CD-36.  Neonatal rats (7 days old) after TBI 
infliction received sRAGE at different time points (15 mins, 3 hours, 12 hours, and 24 
hours)(Chapter 1, Figure 4).  Forty-eight hours post-TBI results revealed that levels of CD-36 
expression in spleen and brain were significantly downregulated in sRAGE-treated TBI animals 
compared to vehicle-treated TBI animals (Chapter 1, Figure 5). Altogether these findings lead us 
to suggest sRAGE antagonistic effects as a therapeutic strategy to reduce TBI related 
inflammation. Thus, we hypothesized that sRAGE administration will reduce secondary 
damaging mechanisms; such as cytokine induced cell death in an in vitro cell culture model.  
 
4.2. Specific Materials and Methods 
 We established an in vitro cell model of secondary inflammation that occurs following 
TBI  by treating human neural progenitor cells with TNF-α, to mimic acute TBI. We treated and 
plated Human Neural Progenitor (hNP1) cells according to the manufacturer’s protocol. We re-
suspended the cells in a total volume of 2 mL of fully supplemented AB2 Neural Medium (pre-
warmed to 37°C). Next we plated them in 2 mL cell suspension of hNP1 cells onto a Matrigel-
coated 35 mm dish and incubated the cells at 37°C in a 5% CO2 humidified incubator. We 
exchanged the medium with fresh fully supplemented AB2 Neural medium at 24 hours post 
plating every other day thereafter. Once the hNP1cells reach 100% confluence, they were 
dissociated manually for passaging (e.g., by gentle and slow pipetting up and down to detach 
the cells). The cells were maintained at a high density, the recommended passaging ratio was 
1:2. After 48 hours 4x104 cells/well/200µL were incubated with 20µL of TNF-α (1.0 µg/mL/200uL 
well) for three days. On the 3rd day hNP1 cells received the different reagent treatments for 3 
hours followed by the calcein and MTT assays: control, TNF-α, sRAGE alone (5µg/mL), and 
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TNF-α plus sRAGE (R&D Systems, 1145-RG-050). Finally we tested the upstream inhibitory 
approach against CD-36 by treating the hNP1 cells with sRAGE. 
 
4.2.1 Measurement of Cell Viability: Calcein-AM Fluorescent Dye 
Measurement of cell viability was performed by both fluorescent live/ dead cell assay 
(Bell, Cao et al. 2003) and trypan blue exclusion method. A two-color fluorescence cell viability 
assay was performed by Calcein-AM (Invitrogen, L3224) to be retained within live cells, 
including an intense uniform green fluorescence and ethidium homodimer (EthD-1) to bind the 
nuclei of damaged cells (bright red fluorescence).  After two hours of reperfusion, the human 
Neural Progenitor Cells (hNP1, Neuromics, Edina, MN) were incubated with 2 mM Calcein-AM 
and 4 mM EthD-1 for 45 min at room temperature in darkness according to the manufacturer’s 
instructions.  Afterwards, cells were washed once with phosphate buffered saline, and then the 
green fluorescence of the live cells was measured by the Gemini EX florescence plate reader 
(Molecular Device), excitation at 485 nm and emission at 538 nm.  In addition, trypan blue 
(0.2%) exclusion method was conducted and mean viable cell counts were calculated in four 
randomly selected areas (1 mm2, n = 10) to further reveal the cell viability. To precisely calibrate 
the cell viability, the values were standardized from fluorescence intensity and trypan blue data. 
 
4.2.2 Measurement of Cell Metabolic Activity: MTT Assay 
To measure metabolic activity we used the a colorimetric assay that measures the 
reduction of yellow 3-(4, 5-dimethyl-2-thiazoyl)-2,5-diphenyltetrazolium bromide (MTT) by 
mitochondrial succinate dehydrogenases. MTT enters the cells and passes into the 
mitochondria where it is reduced to an insoluble, colored (dark purple) formazan product. The 
cells are then solubilized with an organic solvent (e.g., isopropanol) and the released, 
solubilized formazan reagent is measured spectrophotometrically. MTT was used as described 
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in our previous report and manufacturer’s instructions (Roche, Catalog Number 11465007001) 
(Kaneko, Shojo et al. 2014). Before completing 2 hours of reperfusion, the cells were incubated 
with 0.5 mg/ml MTT at 37°C and 5% CO2, and incubated with lysis buffer overnight in a 
humidified atmosphere at 37°C and 5% CO2. The optical density of solubilized purple formazan 
was measured at 570 nm on a Synergy HT plate reader (Bio-Tex). The relative viability of the 
treated cells as compared to the control cells was expressed as the % viability, using the 
following formula: 
[A570 of treated cells] 
[A570 of control cells] 
 
The purpose of the MTT assay was to indirectly assess cell viability by measuring MTT 
reduction only in metabolically active cells. 
 
4.2.3 Data Analysis 
 Statistical analysis included the use of an unpaired two-sided t-test, and a one-way 
analysis of variance (ANOVA) to analyze cell viability and mitochondrial function effects in each 
experimental group versus its respective control group. Group comparisons were done with 
95% CI followed by subsequent pair-wise comparisons using post hoc Bonferonni test. All data 
are presented as mean values ± SEM. Statistical significance was set at p<0.05 for all analyses. 
 
4.3. Results  
Using the calcein assay to reveal cell viability, ANOVA revealed significant treatment 
effects on cell survival of hNP1 cells (F(3,16)=8.709, p values<0.0015, Figure 17 ).  Pairwise 
comparison via Bonferroni’s multiple comparison test showed statistical significance among the 
following treatment groups: control vs. TNF-α, control vs. TNF-α + sRAGE and TNF-α vs. 
sRAGE (p<0.0012). However, there were no significant effects in cell viability when comparing 
x 100 
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TNF-α treated group against the TNF-α + sRAGE group (p >0.05), indicating sRAGE did not 
rescue against TNF-α induced toxicity. Overall these data from the calcein assay demonstrate 
significant cell survival of hNP1 cells under ambient condition when treated with the drug 
sRAGE, but not under TNF-α mediated injury condition. Thus, under the given sRAGE dose, it 
did not appear to rescue hNP1cells from cell death after TNF-α insult.  
Using the MTT assay to measure mitochondrial activity, ANOVA revealed significant 
treatment effects on the level of metabolic activity of hNP1 cells (F(3,16)=42.135, p<0.001, Figure 
18). Bonferroni’s multiple comparison test showed statistical significance in the mitochondrial 
activity of the following treatment groups: Control vs. TNF-α, control vs. TNF-α + sRAGE, TNF-α 
vs sRAGE, and TNF-α + sRAGE vs. sRAGE alone (p values <0.05). However, similar to the 
calcein assay, MTT assays revealed that sRAGE did not rescue against TNF-α induced toxicity 
(p>0.05). 
 
4.4. Discussion  
Our findings indicate that after the TNF-α insult there was significant cell death of hNP1 
cells when compared to control. Treatment with sRAGE was well tolerated by hNP1 cells grown 
under normal cell culture condition, based on their relative cell viability comparable to that of 
control, suggesting the given sRAGE dose was safe. However, treatment with sRAGE did not 
suppress TNF-α induced cell death. These sRAGE and TNF-α interactions observed in the cell 
death were reflected in both calcein and MTT assays (Figures 17and 18). sRAGE and 
endogenous secretory RAGE (esRAGE) are associated with components of metabolic 
syndrome or atherosclerosis in the absence of diabetes (Koyama, Shoji et al. 2005; Koyama, 
Tanaka et al. 2014).A second therapeutic effect of sRAGE that may be further exploited is its 
ability to reverse vascular leakage. 
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Figure 17. In Vitro hNP1 cells relative cell viability Calcein assay using sRAGE. sRAGE 
treatment and CD-36 inhibitory action was well tolerated by hNP1 cells. The data obtained was 
analyzed statistically using one-way analysis of variance (ANOVA) for group comparisons with 
95% CI followed by subsequent pair-wise comparisons using post hoc Bonferonni test. All data 
are presented as mean values ± SEM. Statistical significance was set at p<0.05 for all analyses. 
Using the calcein assay to reveal cell viability, ANOVA revealed significant treatment effects on 
cell survival of hNP1 cells ( F(3,16)=8.709, p < 0.0015). Pairwise comparison via Bonferroni’s 
multiple comparison tests showed statistical significance among the following treatment groups: 
control vs. TNF-α, control vs. TNF-α + sRAGE and TNF-α vs. sRAGE. 
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Figure 18. In Vitro hNP1 cells relative metabolic activity MTT assay using sRAGE. The 
hNP1 cells treated with TNF-α +sRAGE had a slightly higher metabolic rate/percent when 
compared to the TNF-α insult. The data was analyzed statistically using multiple comparison 
test one-way analysis of variance (ANOVA) for group comparisons with 95% CI followed by 
subsequent pair-wise comparisons using post hoc Bonferonni test, (F(3,16)=42.135, p<0.001). 
All data are presented as mean values ± SEM. Statistical significance was set at p<0.05 for all 
analyses. 
 
 
Various animal studies have validated the beneficial effects of sRAGE. One of these 
benefits is neuroprotection. Rodents and human models of ischemic stroke and atherosclerosis 
have identified neuroprotective benefits of a soluble form of receptor for advanced glycation end 
products. One study reported that plasma levels of sRAGE and high mobility group box 1 
(HMGB1) were significantly increased within 48 hours after stroke, and the sRAGE level was an 
independent predictor of functional outcome at 3 months post-stroke (Tang, Wang et al. 2013).  
Furthermore, atherosclerotic studies carried in diabetic mice showed an inhibition of 
atherosclerotic plaques  by the competition of RAGE with sRAGE, suggesting that plasma.  
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In an accelerated atherosclerotic diabetic mice model, sRAGE ameliorated vascular 
lesions in diabetic/atherosclerotic animals in the absence of changes in plasma lipids or 
glycemia (Wautier, Zoukourian et al. 1996). Additionally, sRAGE shows beneficial effects in 
reversing vascular leakage in the intestine, skin of rodent diabetic models (Wautier, Zoukourian 
et al. 1996; Schmidt, Yan et al. 1999). Similarly, a human clinical study using long term 
combined therapy of antihypertensive drugs, nifedipine-telmisartan, showed a beneficial effect 
in increasing sRAGE plasma levels, thus exerting an atheroprotective and anti-inflammatory 
activity (Falcone, Buzzi et al. 2012). The drug sRAGE may be a promising therapeutic drug in 
reducing atherosclerotic plaque formation in patients who may have suffer stroke, in the 
presence or absence of risk factor conditions, such as diabetes and high cholesterol. There are 
other antioxidant agents as alternative treatment regimens to abrogate CD-36.  
A recent study suggests the antioxidant agent, SS-31, as an alternative treatment to 
downregulate CD-36 expression. The molecule SS-31 showed a reduction in CD-36 insidious 
action, and ischemia-induced injury (Cho, Szeto et al. 2007); in addition, SS-31 and related 
compounds were proposed as neuroprotective agents. These compounds target cardiolipin, a 
complex lipid (diphosphatidylglycerol lipid) on the inner mitochondrial membrane (IMM) involved 
in optimization of the electron transport chain (ETC), SS-31 and related compounds are capable 
of restoring cellular metabolism in aging and diverse disease models without affecting the 
normal health of an organism (Szeto and Birk 2014). Both SS-31 and sRAGE may have 
beneficial effects in stroke and related inflammatory disorders. For the use of inhibitors of IL-6, 
such as tocilizumab or a TNF-α inhibitor like etanercept, is a fusion protein produced by 
recombinant DNA, an FDA approved drug to treat rheumatoid arthritis. Etanercept may prove 
beneficial in the long-term treatment of chronic TBI. These inhibitors can also be administered 
IV. Anti-TNF therapy has proven beneficial in the long-term treatment of rheumatoid arthritis and 
it may also work to treat the chronic neuroinflammation present in traumatic brain injury. 
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Additional studies are warranted to fully reveal the efficacy of sRAGE not just for in vitro 
models, but also in vivo animal models to address neurobehavioral effects coupled with the 
detection of sRAGE in the brain. In an in vitro cell model, it may pose as a challenge to assess 
drug adverse effects.  On the other hand, such in vitro model may allow examination of 
sRAGE’s mechanisms of action.  Our in vitro experiment showed sRAGE had no effect on TNF-
α induced cell death treatment. Following TNF-α treatment, hNP1 cells exhibited reduced cell 
viability.  Unfortunately, the TNFα-treated cells exposed to sRAGE showed a small, non-
significant increase in cell viability when compared to TNF-α alone. This may be indicate further 
testing at higher sRAGE doses or manipulating the timing of TNF-α and sRAGE initiation in 
order to capture the true effects of sRAGE against inflammation. Alternatively, sRAGE may 
exert other mechanisms of action affecting parallel molecular or cellular pathways leading to 
neuroprotection that may not have been captured by simple calcein and MTT assays.  More 
sensitive cell viability and cell death pathway tests may be needed.  In addition, further in vivo 
testing would be necessary to reveal behavioral and toxicity effects before and after sRAGE 
administration in an in vivo TBI animal model to assess neuronal survival, functional recovery 
and any adverse effects of sRAGE.  
The present in vitro study provides the basis for pursuing more in-depth studies on 
sRAGE and inflammatory-based therapies directed at sequestering the secondary cell death 
associated with TBI. Further studies should focus on CD-36 inhibition via s-RAGE in a pre-TBI 
prophylactic approach to test for any neuroprotective effects. Although sRAGE cannot cross the 
healthy blood brain barrier (BBB), his barrier is compromised after TBI and the immediate 
treatment with sRAGE thereafter may allow the drug to easily reach the injured brain site. 
Alternatively, even if sRAGE is not able to cross the BBB after acute TBI, we envision sRAGE 
can afford inhibitory action to downregulate CD-36 expression in the spleen, which we 
discussed earlier as contributing to the systemic inflammation in TBI.   
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To that end, it is possible to think that sRAGE will act on the periphery (i.e., spleen) and 
significantly reduce infiltrating immune/inflammatory cells destined to exacerbate the brain 
inflammation after TBI. In parallel, investigations on drugs that similarly target CD-36 
inflammation may reveal new avenues of TBI research.  Anti-inflammatory drugs like IL-6 
inhibitors, such as tocilizumab, or TNF-α inhibitors like etanercept, as adjunctive therapy may 
improve sRAGE therapeutic outcome in TBI. The modest effects of sRAGE against TNFα-
induced toxicity suggest that sRAGE alone may not be protective against TBI. Increasing the 
dose and altering the drug initiation regimen may improve sRAGE efficacy in TBI.  Similarly, 
stem cell therapy in combination with sRAGE or SS-31 could potentially augment inflammation 
while promoting neurogenesis. True to our long-standing interest in stem cell therapy, we 
extended our hypothesis to test sRAGE in combination with stem cells (Chapter 5) to reveal the 
efficacy of this combination therapy. In particular, we next investigated human neural progenitor 
stem cells combined with sRAGE to assess any synergistic effects of these two treatments on 
cell viability and metabolic cell activity. 
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CHAPTER 5 
STEM CELL THERAPY IN COMBINATION WITH SRAGE MAY AMELIORATE SECONDARY 
INFLAMMATION THAT MEDIATES TBI INJURY IN-VITRO CELL MODEL OF TBI  
 
5.1 Introduction 
 Head trauma and long-term cognitive decline has been addressed for years by 
epidemiological and clinical studies. Follow up of patients 10-20 years after admission to 
hospital with TBI provided further evidence of late stage neurodegeneration (Millar, Nicoll et al. 
2003; Smith, Gentleman et al. 2012). In addition studies demonstrate that prolonged microglial 
activation is a feature of traumatic brain injury, but that the neuroinflammatory response returns 
to control levels after several years (Smith, Gentleman et al. 2012). Furthermore, a recent in 
vivo rat study demonstrated prolonged pathological outcomes 60 days after experimental TBI 
characterized by elevated inflammation and suppressed neurogenesis (Acosta, Tajiri et al. 
2013).  
Based on our previous results (Chapter 4), sRAGE had no effects against TNFα-induced 
toxicity suggesting that sRAGE alone may not be efficacious against inflammation TBI. 
Augmenting sRAGE dose and adjusting its administration in a timely manner may increase 
sRAGE efficacy in TBI.  An alternative therapy is to combine sRAGE with other anti-
inflammatory drugs, which may possibly improve CD-36, as well as non-CD-36, inhibitory 
effects of sRAGE.  Likewise, stem cell therapy in combination with sRAGE/or SS-31 could 
substantially increase inflammation, yet promote neuronal cell survival/neurogenesis. We 
studied the use of human neural progenitor stem cells combined with sRAGE, to determine any 
concerted effects of these two treatments on cell viability and metabolic cell activity.  
89 
Accumulating evidence in stroke studies has implicated the mobilization of bone marrow 
(BM)-derived stem cells to promote regeneration in damaged brain regions (Borlongan, Glover 
et al. 2011). These cells have the extraordinary ability to travel from the bone marrow (BM), thru 
the peripheral circulatory system, to eventually enter the injured brain, and secrete 
neuroprotective growth factors that promote cell survival/rescue neurons from cell death. Among 
the repertoire of bone marrow derived stem cells (BMDSCs) we have: hematopoietic stem cells 
(HSCs), mesenchymal stem cells (MSCs), and endothelial progenitor cells (EPCs) and very 
small embryonic-like cells (VSELs).  These have been demonstrated to exert therapeutic 
benefits in animal models of stroke (Yasuhara, Matsukawa et al. 2006; Hess and Borlongan 
2008; Hess and Borlongan 2008), human stroke clinical trials (Kondziolka, Wechsler et al. 2000; 
Meltzer, Kondziolka et al. 2001; Nelson, Kondziolka et al. 2002), and in other models of 
neurological diseases like epilepsy (Venturin, Greggio et al. 2011), Parkinson’s disease (Khoo, 
Tao et al. 2011; Danielyan, Beer-Hammer et al. 2014), and Alzheimer’s disease (Nikolic, Hou et 
al. 2008; Danielyan, Beer-Hammer et al. 2014).  Encouraging outcomes of the latest TBI animal 
studies using BMDCs’ transplantation have demonstrated efficacious delivery of human 
BMDSCs to the injured brain region in rats; grafted cells were delivered using collagen delivery 
matrices which seem to facilitate cell survival and neurite outgrowth post-transplantation (Guan, 
Zhu et al. 2013). Another interesting outcome is increased glucose metabolism which may 
rescue damaged neurons from cell death in an acute CCI animal model of TBI (Park, Yoon et al. 
2013). Finally, last BM-derived endothelial progenitor cells promote axonal survival and 
microvascular maintenance of the white matter after midline fluid percussion injury in adult rats 
(Park, Park et al. 2014). Thus, stem cell therapy in combination with sRAGE, in particular 
human bone marrow derived stem cells could decrease neuronal loss, ameliorate inflammation 
and promote neuroprotection in TBI and other brain related diseases. 
  In accord with our hypothesis that upregulated CD-36 contributes to inflammation (Aim 
1), and inhibition of inflammation via pharmacologic regimens (i.e., sRAGE) (Aim 2), in this Aim, 
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we further hypothesized that inflammation-induced impairment TBI can be rescued by stem cell 
therapy. Here, we additionally tested whether stem cell therapy alone or in combination with 
sRAGE targeting human cells (i.e., human neural progenitor cells or hNP1), synergistically 
reduced cell death and increased metabolic cell activity. Using the same dose of sRAGE 
(Chapter 4), and stem cells known to afford therapeutic benefits in CNS disorders (Thorne and 
Frey 2001; Lee, Lee et al. 2013; Acosta, Tajiri et al. 2014)), we tested their stand-alone and 
combined efficacy in an in vitro model of inflammation, which is considered to replicate a major 
secondary cell death process associated with TBI.  
 
5.2 Specific Materials and Methods 
   Our in vitro cell model of inflammation cell model of TBI involved treating hNP1 cells with 
TNF-α, to mimic acute TBI. We treated and plated hNP1 cells according to the manufacturer’s 
protocol. We re-suspended the cells in a total volume of 2 mL of fully supplemented AB2 Neural 
Medium (pre-warmed to 37°C). Next, we platted them the 2 mL cell suspension of hNP1 cells 
onto a Matrigel-coated 35 mm dish and incubated the cells at 37°C in a 5% CO2 humidified 
incubator. We exchanged the medium with fresh fully supplemented AB2 Neural medium 24 
hours post plating. We exchanged with fresh medium every other day thereafter. Once the 
hNP1 cells reach 100% confluence, they were dissociated manually for passaging (e.g., by 
gentle and slow pipetting up and down to detach the cells). The cells were maintained at a high 
density, the recommended passaging ratio was 1:2. After 48 hours 4x104 cells/well/200µL were 
incubated with 20µL of TNF-α (1.0 µg/mL/200µL well) for three days.  On the 3rd day hNP1 cells 
received the various reagent treatments for 3 hours, and later underwent the calcein and MTT 
assays: control, TNF-α only, TNF-α plus sRAGE (5µg/mL) (R&D Systems, 1145-RG-050) plus 
human bone marrow derived stem cells (BMDSCs) at a concentration of 2x104 cells in a 20µL 
volume (Progenitor Cell Therapy, California), TNF-α in combination with BMDSCs, and 
BMDSCs alone.    
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5.2.1 Measurement of cell viability: Calcein-AM fluorescence dye 
Measurement of cell viability was performed by both fluorescent live/ dead cell assay 
(Bell, Cao et al. 2003) and trypan blue exclusion method.  A two-color fluorescence cell viability 
assay was performed by Calcein-AM (Invitrogen, L3224) to be retained within live cells, 
including an intense uniform green fluorescence and ethidium homodimer (EthD-1) to bind the 
nuclei of damaged cells (bright red fluorescence).  After two hours of reperfusion, the hNP1 cells 
(Neuromics, Edina, MN) were incubated with 2 mM Calcein-AM and 4 mM EthD-1 for 45 min at 
room temperature in darkness according to the manufacturer’s instructions.  Afterwards, cells 
were washed once with phosphate buffered saline, and then the green fluorescence of the live 
cells was measured by the Gemini EX florescence plate reader (Molecular Device), excitation at 
485 nm and emission at 538 nm.  In addition, trypan blue (0.2%) exclusion method was 
conducted and mean viable cell counts were calculated in four randomly selected areas (1 mm2, 
n = 10) to further reveal the cell viability. To precisely calibrate the cell viability, the values were 
standardized from fluorescence intensity and trypan blue data. 
 
5.2.2 Measurement of Mitochondrial Activity: MTT Assay  
To measure metabolic activity we used the mitochondrial activity assay by the  reduction 
of 3-(4, 5-dimethyl-2-thiazoyl)-2,5-diphenyltetrazolium bromide (MTT) by cellular 
dehydrogenases was used as described in our previous report and manufacturer’s instructions 
(Roche, Catalog Number 11465007001) (Kaneko, Shojo et al. 2014). Before completing 2 hours 
of reperfusion, the cells were incubated with 0.5 mg/ml MTT at 37°C and 5% CO2, and 
incubated with lysis buffer overnight in a humidified atmosphere at 37°C and 5% CO2. The 
optical density of solubilized purple formazan was measured at 570 nm on a Synergy HT plate 
reader (Bio-Tex). The purpose of the MTT assay was to assess cell viability after treating cells 
with sRAGE. 
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5.2.3 Data Analysis 
 Statistical analysis assessed cell viability and mitochondrial functional effects in each 
experimental group versus its respective control group. Group comparisons included the use a 
one-way analysis of variance (ANOVA) with 95% CI followed by subsequent pair-wise 
comparisons using post hoc Bonferonni test. All data are presented as mean values ± SEM. 
Statistical significance was set at p<0.05 for all analyses. 
 
5.3. Results  
Using the calcein assay to reveal cell viability, ANOVA revealed significant treatment 
effects on cell survival of hNP1 cells (F(4,20)=20.789, p values<0.0001) (Figure 19).  Pairwise 
comparison via Bonferroni’s multiple comparison test showed statistical significance among the 
following treatment groups: control vs. TNF-α, TNF-α + sRAGE+BMDSCs, TNF-α+ BDMSCs, 
and BDMSCs only groups against TNF-α (p<0.0001).  There were no significant effects in cell 
viability when comparing the following treated groups: TNF-α+sRAGE+BMDSCs, TNF-α+ 
BMDSCs, and BMDSCs only against control (p>0.05).  Overall these data from the calcein 
assay demonstrate significant cell survival of hNP1 cells under stem cell conditions than when 
treated with the drug sRAGE alone.  Moreover, combination therapy did lead to better survival 
compared to TNF-α alone. Once again, the given sRAGE dose did not appear to have rescued 
hNP1 cells from cell death after TNF-α insult (as in Chapter 4). Yet, stem cells conveyed 
neuroprotection by rescuing hNP1cells, as seen in the increased cell viability. In summary, 
these data from the calcein assay show significant cell survival of hNP1 cells when treated with 
the drug sRAGE in combination with stem cells, but also by stem cells alone after TNF-α insult. 
Although sRAGE did not seem to exacerbate TNF-α toxicity, neither to hNP1 cells nor to stem 
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cells, the given sRAGE dose did not appear to have rescued hNP1 cells from cell death after 
TNF-α treatment.  
Meanwhile in the MTT assay designed to measure mitochondrial activity, ANOVA revealed 
significant treatment effects on the level of metabolic activity of hNP1 cells (F(4,20)=545.1345, 
p<0.0001) (Figure 20). Bonferroni’s multiple comparison test showed statistical significance in 
the mitochondrial activity of the following treatment groups: Control vs. TNF-α, control vs. TNF-α 
+ sRAGE+BMDSCs, control vs. TNF-α + BMDSCs, control vs. BMDSCs, TNF-α vs. TNF-α + 
sRAGE+BMDSCs, TNF-α vs. TNF-α + BMDSCs, TNF-α vs. BMDSCs (one way analysis of 
variance, p<0.0001). Taken as a whole, data from the MTT assay demonstrate significant 
metabolic activity of hNP1 cells under stem cell conditions than when treated with the drug 
sRAGE alone.  Moreover, combination therapy did point to increased metabolism compared to 
TNF-α alone. Once again, the given sRAGE dose did not appear to have rescued hNP1 cells 
from dysfunctional metabolic activity after TNF-α insult (as in Chapter 4). Yet, stem cells 
afforded neuroprotection by rescuing hNP1 cells, as seen in the increased metabolic activity. In 
closing, these data from the MTT assay showed significant increase in metabolic activity of 
hNP1 cells after TNF-α insult when treated with the stem cells alone, without enhancement 
when combined with sRAGE. Although sRAGE did not seem to exacerbate TNF-α toxicity, 
neither to hNP1 cells nor to stem cells, the given sRAGE dose did not appear to have rescued 
hNP1 cells from deficient mitochondrial activity after TNF-α treatment.  
 
5.4 Discussion 
Results from our in vitro model of inflammation, a secondary cell death process of TBI, 
demonstrated the therapeutic effects of stem cells against inflammation. BMDSCs are 
efficacious after the TNF-α insult to hNP1 cells, in that stem cells alone or in combination with 
sRAGE increased cell viability and metabolic activity compared to control and the TNF-α treated 
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group. We initially envisioned that stem cells would act synergistically with sRAGE, a compound 
shown to block TBI related inflammation. 
 
 
 
Figure 19. In Vitro hNP1 cells relative cell viability Calcein assay using stem cells. sRAGE 
treatment and stem cell therapy increased neuronal cell survival. The hNP1 cells treated with 
TNF-α +sRAGE+BMDSCs had increased cell viability when compared to the TNF-α only, and 
the TNF-α +BMDSCs groups. The data obtained was analyzed statistically using one-way 
analysis of variance (ANOVA) (F(4,20)=20.789, p values<0.0001) for group comparisons with 
95% CI followed by subsequent pair-wise comparisons using post hoc Bonferonni test. All data 
are presented as mean values ± SEM. Statistical significance was set at p<0.05 for all analyses. 
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Figure 20. In Vitro hNP1 cells relative metabolic activity MTT assay using stem cells. The 
hNP1 cells were treated with TNF-α +sRAGE+BMDSC had increased metabolic rate when 
compared to the TNF-α only, and TNF-α +BMDCS groups. The data was analyzed statistically 
using multiple comparison test one-way analysis of variance (ANOVA) for group comparisons 
with 95% CI followed by subsequent pair-wise comparisons using post hoc Bonferonni test 
(F=545.1, df=4). All data are presented as mean values ± SEM. Statistical significance was set 
at p<0.05 for all analyses. 
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However, there was no detectable significant increase in cell survival and mitochondrial 
activity between combination therapy and stem cells alone in TNF-α treated cells, indicating 
absence of synergistic effects of sRAGE and stem cells in abrogating inflammation. Moreover, 
sRAGE alone did not increase cell survival and mitochondrial activity in TNF-α treated cells   (as 
in Chapter 4). These findings suggest that while sRAGE was not effective in affording direct 
therapeutic benefits to hNP1 cells against inflammation, stem cells alone were able to reduce 
inflammation to some extent.   
 Previous in vitro and in vivo studies reveal that low levels of  sRAGE are  not only 
associated with conventional risk factors (diabetes, hypertension, hypercholesterolemia), non-
diabetic coronary artery disease, stroke, and AD (Yamagishi and Matsui 2010; Colhoun, 
Betteridge et al. 2011), but also to acute ischemic stroke, in particular without the source of 
cardioembolism (Park, Yun et al. 2009). Hence, in the clinical setting measuring plasma levels 
of sRAGE after stroke, and TBI may be useful as a predictor of the neurological severity of the 
condition, especially in subjects without identifiable conventional risk factors. In contrast, a 
recent report suggests that high serum sRAGE levels in pregnant women may be associated 
with recurrent pregnancy losses (RPL). sRAGE contributes to RPL by reducing uterine blood 
flow and subsequently causing ischemia in the fetus via inflammatory and thrombotic reactions 
(Ota, Yamagishi et al. 2014). That the present study revealed that sRAGE neither exert 
neuroprotection against nor exacerbate TNF-α neurotoxicity suggests that optimal dose and 
timing may need to be adjusted to fully capture the functional effects of sRAGE in inflammation 
following TBI.  
A bulk of the literature also shows multiple neuroprotective effects of stem cells against 
inflammation in various diseases including TBI. These stem cells include using human 
mesenchymal stem cells (hMSCs), human neural stem cells (hNSCs) and human adipose stem 
cells (hASCs). These altogether possess overlapping abilities: i) hMSCs  protect  hyperoxia-
induced lung injury via downregulation of the RAGE-NF-KB signaling in the lung of newborn rats 
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(Tian, Ji et al. 2012); ii) an intrinsic ability of MSCs  for multipotent differentiation as potential  
therapy option for various diseases, including those of the musculoskeletal, neuronal, 
cardiovascular and pulmonary systems (Akram, Samad et al. 2013; Zou, Zhang et al. 2014); iii) 
MSCs paracrine ability to secrete an array of factors implicated in the mitigation of pathological 
conditions through anti-inflammatory, anti-apoptotic and immunomodulatory mechanisms (Zou, 
Zhang et al. 2014); iv) human neural stem cells have improved symptomatic inflammation in 
early-stage ischemic-reperfusion cerebral injury in mice (Huang, Wong et al. 2014).  
The drug sRAGE had inconsequential effects against TNF-α induced toxicity suggesting 
that sRAGE alone may not shield against TBI. Drug efficacy may be attained by adjusting 
sRAGE dose and early drug administration when treating TBI.  The use of other anti-
inflammatory drugs along with sRAGE may enhance its, inhibitory effects against TBI related 
inflammation.  Likewise, stem cell therapy in combination with sRAGE/or SS-31 could effectively 
increase inflammation while promoting neurogenesis. Our long-standing interest in stem cell 
therapy advances the present hypothesis of testing sRAGE in combination with stem cells to 
unravel the efficacy of this combination therapy. This study solicits additional experiments in 
demonstrating the role of sRAGE as stand-alone or adjunct therapy for enhancing cell viability 
and metabolic cell activity against inflammation and TBI.  Although the present data revealed 
that sRAGE alone was not neuroprotective against TBI, we established that stem cells may 
abrogate TBI-induced inflammation, and suggesting sRAGE as a potential pharmacological 
agent for treating inflammation in TBI.     
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CHAPTER 6 
DISCUSSION 
 
6.1 Relevance of CD-36  
 CD-36 is of interest as a therapeutic target molecule because of its inflammatory role in 
lipid and metabolic conditions, cardiovascular disorders, and very recently in glucose 
intolerance, cerebrovascular conditions, and neurodegenerative diseases. Inflammation is a 
common factor among all these conditions, and also in head injuries, such as TBI. Our main 
goal is to observe any CD-36 related changes after post-traumatic inflammation that follows the 
secondary brain damage associated with TBI. CD-36 has significant roles in different stages of 
previously mentioned diseases; we focus mainly on its inflammatory component, making it an 
important molecule for therapeutics. 
 
6.2 CD-36, Inflammation and TBI 
 Experiments detailed in this dissertation have detected increased CD-36 near the area 
of impact after TBI. This expression reaches a peak in the early time periods after injury, in 
particular after 24 hours post-TBI up to 7 days post-TBI. This suggests CD-36’s role is in acute 
neuroinflammation. Other inflammatory mediators, such as MCP-1 and Iba-1, CD-36 
immunoreactivity showed a stronger upregulation in cells in the area of brain impact at acute 
time-points versus the chronic TBI period. The chronic group, 60-days post-TBI, barely showed 
expression of CD-36 in cortical brain areas. Thus, this may indicate decay in CD-36 involvement 
in the inflammatory process seen in chronic TBI. The early expression of CD-36 hours after TBI 
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injury may also indicate a therapeutic window for TBI within the first couple of hours when 
targeting CD-36 mediated neuroinflammation. 
 Furthermore, we detected another novel observation, the co-localization of CD-36 with 
NeuN. We interpret these findings as straight action of CD-36 in mediating inflammation, and 
eventually cell death, in neurons in brain cortical regions. Quite the opposite, there was minimal 
co-localization of CD-36 with GFAP implying that CD-36 minimally contributes to astrocytic-
mediated inflammation. Yet, there are experiments reporting that TBI-exposed MCP-1 knockout 
mice showed no co-localization of MCP-1 with NeuN and GFAP in the cortex within 4 days of 
TBI; but, there was co-localization of MCP-1 with a subset of F4/80-positive amoeboid 
macrophages accumulating in the lesion site (Rhodes, Sharkey et al. 2009; Semple, Bye et al. 
2010). More studies are necessary to further characterize what types of cells are influenced by 
CD-36 over-expression, which will help us understand CD-36-mediated inflammation and its 
treatment. Thus, CD-36 may have an essential role in the neuroinflammatory cascade that 
further contributes to the pathology of TBI.  
 The process of neuroinflammation involves a vast series of events contributing to 
progressive brain degeneration. Our gathered results suggest a tangible association between 
CD-36 and MCP-1 after TBI. MCP-1 is associated in macrophage recruitment into damaged 
brain tissue after TBI. In addition, we observed a trend of increased CD-36 protein expression in 
early acute TBI time points (i.e., 24-48 hours, and 7 days) in the brain, which may cue the 
change of functional effects of this immune response from pro-survival to cell death. In contrast, 
we observed a low CD-36 expression in the 60 day chronic post TBI group. This could possibly 
be a delayed response of peripheral macrophages to arrive at the site of injury. This has been 
observed in stroke studies of mononuclear phagocytes (resident microglia) accumulated in the 
injured brain within  3 to 4 days when compared to blood-derived macrophages at 6 to 7 days 
(Schroeter, Jander et al. 1997). This explains brain protein levels, yet it does not justify CD-36 
downregulation in the spleen after 48 hours and 7 days post- TBI.   In general, our experiments 
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of CD-36 expressing monocytes in the spleen after TBI may help us clarify CD-36 role in the 
peripheral immune response. We already know that the spleen’s response exacerbates the 
inflammatory response post-TBI from the multiple experiments linking the spleen’s response to 
cerebrovascular conditions, such as ischemic stroke. Likewise, CD-36 may also play a key role 
in the inflammatory splenic response after TBI. Our results suggest an intimate involvement of 
CD-36 mediated inflammation in TBI, providing novel insights into the understanding of disease 
neuroinflammation and as a potent therapeutic target for TBI treatment.  
 Further examination of CD-36 protein expression levels in the spleen during acute TBI 
time- points showed no significant differences in protein levels between TBI and sham animals 
at each time-point. Although a CD-36 peak splenic expression occurred primarily at 24 hrs in the 
TBI, there was no significant difference between TBI and sham groups. Likewise, there were no 
significant differences when comparing TBI vs. sham at 48 hrs and 7 days post-TBI. We 
presume this initial splenic response peaking within the first 24 hrs is CD-36 mediated, followed 
by a slow decay at later time points. One explanation for the CD-36 splenic protein 
downregulation in the spleen of acute time points after the initial 24 hrs increase may be that 
different kind of monocytes get activated by other inflammatory signaling pathways over those 
CD-36 mediated monocytes subsets. A recent study found temporal differences in peripheral 
immunity after TBI in a murine model of closed head injury at early time points (1-7days) and 
later ones (30 days and 60 days) after injury (Schwulst, Trahanas et al. 2013).  
 Our study had limitations, a small number of animals to account for CD-36 expression in 
the spleen; this may be a reason why we observed no difference. If we were to increase sample 
size, we may be able to observe a significant increase in CD-36 protein expression among the 
acute and sham groups. There are also other cellular events and molecular interactions of CD-
36 with other pro-inflammatory and anti-inflammatory cytokines/chemokines that may be 
responsible for CD-36 downregulation in the spleen. Prompt detection of CD-36 and related 
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inflammatory mediators in serum and plasma of TBI patients and TBI rodents, will redirect new 
avenues for clinical translation of CD-36 as a screening biomarker.  
 Our observations corroborate the upregulation of brain and splenic CD-36 mediated 
activation in the first 24 hours after TBI. Nevertheless the increased CD-36 brain response is 
sustained until 7 days post-TBI and then declines. In contrast, splenic CD-36 expression 
remains unchanged even after days of injury, but it declines after 1 day. The expression of CD-
36 with the studied inflammatory markers indicate mainly the activation of MCP-1 and Iba-1, 
suggesting macrophage activation, certain/minimal astrocyte activation in the brain cortex, and 
microglia activation associated to other inflammatory mechanisms after TBI. In addition, the 
chronic 60-Day post TBI group showed very low expression levels of CD-36 in the cortex (and 
spleen), implying that CD-36 has a minimal role in chronic inflammation, but is more relevant in 
the acute stages of TBI.  
 Future objectives in the study of CD-36 as an inflammatory mediator may expand on 
how CD-36 regulates the mobilization of various monocyte subset populations by interacting 
with other pro-inflammatory cytokines/chemokines and their receptors, such as CCR2. It will be 
interesting to record temporal profiles of cytokines/chemokines influencing monocyte subsets in 
the brain and spleen of TBI animal models, and at the same time compare them to groups of 
animals subjected to splenectomy, as these observations may provide further insights on the 
inflammation-mediated pathology and treatment of TBI. Additionally, in vitro studies may be 
conducted to block CD-36 and record any differences on monocyte subsets, their ability to 
acquire a particular phenotype in circulation, and their peripheral influence after injury. There 
are also pharmacological approaches using specific CD-36 inhibitor, which would contribute 
allow a much better understanding of CD-36 target engagement effects. We also recognized 
that the major limitation in this study included small sample size, which likely affected the 
statistical analyses of CD-36 protein expression. Alternatively, the lack of alteration in CD-36 
expression may be due to a rapid upregulation or decline associated with the supra-acute 
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period post-TBI not captured in this study. Nonetheless, these results demonstrated that CD-36 
closely accompanied the inflammation in the acute TBI period (24 hours to 7 days).  
 
6.3 Effects of sRAGE in an in vitro cell model of Inflammation 
 Using an in-vitro cell model we did not observe a role for the soluble receptor of 
advanced end-glycation product (sRAGE) in the inflammatory response after TBI. In our 
previous in-vitro experiments we found out that inhibitory action of soluble receptor of advanced 
glycation end products (sRAGE) in various cell types, suggesting sRAGE as a useful drug to 
reduce TBI related inflammation. These may attenuate the immune response and tissue injury. 
Our pilot experiments suggest/demonstrate the inflammatory role of CD-36 as the link shared by 
stroke and TBI. This CD-36 mechanism may be a candidate therapeutic target to reduce 
secondary cell death in TBI, and promote functional and cognitive brain recovery.  We decided 
to focus on sRAGE because of its strong affinity for CD-36 (Marsche, Zimmermann et al. 2003),  
its synergistic anti-inflammatory effect combined with long term use of antihypertensive drugs 
like nifedipine and telmisartan (Falcone, Buzzi et al. 2012); and sRAGE ability to act as a decoy 
for RAGE to slow carotid artery bloom injury, slow atherosclerosis via blocking RAGE, and avoid 
interaction of RAGE with its pro-inflammatory ligands (AGEs, HMGB1, S100 proteins) (Maillard-
Lefebvre, Boulanger et al. 2009). Recent human studies propose sRAGE as a candidate in the 
prognosis and follow up after ischemic and hemorrhagic stroke (Qian, Ding et al. 2012; Menini, 
Ikeda et al. 2013; Tang, Wang et al. 2013). These studies reveal: a)ischemic and hemorrhagic 
stroke patients have an increase in sRAGE serum levels days after stroke  (ranged between 
26%-296%, p<0.001), and this change paralleled recovery and recurrence or aggravation of the 
episodes (Menini, Ikeda et al. 2013); b)  acute ischemic stroke patients, C57BL/6J mice, and 
primary cortical neurons subjected to oxygen and glucose deprivation showed increased 
sRAGE plasma levels within 48hours of injury; furthermore, sRAGE recombinant administration 
(intravenously) was effective in reduction of infiltrating immune cells, improving the outcome of 
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injury in mice, and protecting cultured neurons against hypoxia and cell death (Tang, Wang et 
al. 2013). In addition, in vivo and in vitro studies indicate that the down-regulation of CD-36 by 
novel class antioxidant peptides may be a useful strategy to treat ischemic stroke victims (Cho, 
Szeto et al. 2007). 
 
6.4 Effects of Combination Stem Cell Therapy and sRAGE 
 The combination of stem cell therapy and sRAGE suggested their positive influence in 
promoting cell survival and ameliorating inflammation as a therapeutic pathway against TBI. 
Altogether, the current literature reinforces the thought that prolonged microglial activation is a 
hallmark of traumatic brain injury, but may also suggest that neuroinflammatory responses 
return to control levels after several years based on the severity of the injury.  
Our findings indicate that after the TNF-α insult there was significant cell death of hNP1 
cells when compared to control. Treatment with sRAGE was well tolerated by hNP1 cells grown 
under normal cell culture condition, based on their relative cell viability comparable to that of 
control, suggesting the given sRAGE dose was safe. However, treatment with sRAGE did not 
suppress TNF-α induced cell death. Various animal studies have validated the beneficial effects 
of sRAGE. One of these benefits is neuroprotection, rodents and human models of ischemic 
stroke and atherosclerosis have identified neuroprotective benefits of a soluble form of receptor 
for advanced glycation end products. One study reported that plasma levels of sRAGE and high 
mobility group box 1 (HMGB1) were significantly increased within 48 hours after stroke, and the 
sRAGE level was an independent predictor of functional outcome at 3 months post-stroke 
(Tang, Wang et al. 2013).  Furthermore, atherosclerotic studies carried in diabetic mice showed 
an inhibition of atherosclerotic plaques by the competition of RAGE with sRAGE, suggesting 
that plasma sRAGE and endogenous secretory RAGE (esRAGE) are associated with 
components of metabolic syndrome or atherosclerosis in the absence of diabetes (Koyama, 
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Shoji et al. 2005; Koyama, Tanaka et al. 2014). A second therapeutic effect of sRAGE that may 
be further exploited is its ability to reverse vascular leakage.  
In an accelerated atherosclerotic diabetic mice model, sRAGE ameliorated vascular 
lesions in diabetic/atherosclerotic animals in the absence of changes in plasma lipids or 
glycemia (Wautier, Zoukourian et al. 1996). Additionally, sRAGE shows beneficial effects in 
reversing vascular leakage in the intestine, skin of rodent diabetic models. (Wautier, Zoukourian 
et al. 1996; Schmidt, Yan et al. 1999). Similarly, a human clinical study using long term 
combined therapy of antihypertensive drugs, nifedipine-telmisartan, showed a beneficial effect 
in increasing sRAGE plasma levels, thus exerting an atheroprotective and anti-inflammatory 
activity (Falcone, Buzzi et al. 2012). The drug sRAGE may be a promising therapeutic drug in 
reducing atherosclerotic plaque formation in patients who may have suffer stroke, in the 
presence or absence of risk factor conditions, such as diabetes and high cholesterol. There are 
other antioxidant agents as alternative treatment regimens to abrogate CD-36. In recent 
experiments the molecule SS-31 showed a reduction in CD-36 insidious action, and ischemia-
induced injury (Cho, Szeto et al. 2007); in addition, SS-31 and related compounds were 
proposed as neuroprotective agents. These compounds target cardiolipin, a complex lipid 
(diphosphatidylglycerol lipid) on the inner mitochondrial membrane (IMM) involved in 
optimization of the electron transport chain (ETC), SS-31 and related compounds are capable of 
restoring cellular metabolism in aging and diverse disease models without affecting the normal 
health of an organism. Both SS-31 and sRAGE may have beneficial effects in stroke and related 
inflammatory disorders. For the use of inhibitors of IL-6, such as tocilizumab or a TNF-α inhibitor 
like etanercept, is a fusion protein produced by recombinant (Szeto and Birk 2014) DNA, an 
FDA approved drug to treat rheumatoid arthritis. Etanercept may prove beneficial in the long-
term treatment of chronic TBI. These inhibitors can also be administered IV. Anti-TNF therapy 
has proven beneficial in the long-term treatment of rheumatoid arthritis and it may also work to 
treat the chronic neuroinflammation present in traumatic brain injury. 
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Additional in vitro and in vivo TBI animal models should continue to look at the efficacy 
of sRAGE, record neurobehavioral and drug adverse effects. In vitro cell models may help 
decipher sRAGE’s mechanisms of action.  Our in vitro experiments showed increased cell 
survival under normal conditions after TNF-α insult and sRAGE treatment. Following TNF-α 
treatment, hNP1 cells exhibited reduced cell viability. Unfortunately, the TNF-α treated cells 
exposed to sRAGE showed a small, non-significant increase in cell viability when compared to 
TNF-α alone. This may be indicate further testing at higher sRAGE doses or manipulating the 
timing of TNF-α and sRAGE initiation in order to capture the true effects of sRAGE against 
inflammation. Alternatively, sRAGE may exert other mechanisms of action beyond inflammation 
affecting parallel molecular or cellular pathways leading to neuroprotection that may not have 
been captured by simple calcein and MTT assays.  More sensitive cell viability and cell death 
pathway tests may be needed.   
In addition, further in vivo testing would be necessary to reveal behavioral and toxicity 
effects before and after sRAGE administration in an in vivo TBI animal model to assess 
neuronal survival, functional recovery and any adverse effects of sRAGE. Our in vitro study 
provides the basis for pursuing more detailed studies on sRAGE, and inflammatory-based 
therapies directed at sequestering the secondary cell death associated with TBI. Although 
sRAGE cannot cross the healthy blood brain barrier (BBB), this barrier is compromised after TBI 
and the immediate treatment with sRAGE thereafter may allow the drug to easily reach the 
injured brain site. Alternatively, even if sRAGE is not able to cross the BBB after acute TBI, we 
envision sRAGE can afford inhibitory action to downregulate the splenic response, which we 
discussed earlier as contributing to the systemic inflammation in TBI.  To that end, it is possible 
to think that sRAGE may act on the periphery (i.e., spleen) and significantly reduce infiltrating 
immune/inflammatory cells destined to exacerbate the brain inflammation after TBI. In parallel, 
investigations on drugs that similarly target CD-36 inflammation may reveal new avenues of TBI 
research.  Such as anti-inflammatory drugs like: the IL-6 inhibitor tocilizumab, and, or the TNF-α 
106 
inhibitor etanercept. Altogether may serve as adjunctive therapy to improve sRAGE therapeutic 
outcome in TBI.  
The modest effects of sRAGE against TNFα-induced toxicity suggest that sRAGE alone 
may not be protective against TBI. Increasing the dose and altering the drug initiation regimen 
may improve sRAGE efficacy in TBI.  Similarly, stem cell therapy in combination with sRAGE or 
SS-31 could potentially augment inflammation while promoting neurogenesis. In our study, 
sRAGE alone was not robustly neuroprotective against TBI. Results from our in vitro model of 
TBI showed limited therapeutic effects of stem cells against inflammation. BMDSCs are 
efficacious after the TNF-α insult to hNP1 cells; when stem cells were used alone or in 
combination with sRAGE cell viability increased compared to control and the TNF-α treated 
group. There was not a notorious increase in cell survival and mitochondrial activity when 
comparing those treated with combination therapy as opposed to stem cells alone.  
These findings suggest that while sRAGE was not effective in affording direct 
therapeutic benefits to hNP1 cells against inflammation, perhaps sRAGE influences   stem cells 
ability to mediate TBI related inflammation. Supporting in vivo studies on increased cell survival 
afforded by certain stem cells against inflammation in various diseases and TBI include using 
human mesenchymal stem cells (hMSCs), human neural stem cells (hNSCs) and human 
adipose stem cells (hASCs) (Tian, Ji et al. 2012; Akram, Samad et al. 2013; Huang, Wong et al. 
2014; Zou, Zhang et al. 2014). Our results indicated no significant difference in cell viability and 
mitochondrial activity in the combined therapy group as opposed to stem cells alone. Our drug 
sRAGE had inconsequential effects against TNFα-induced toxicity suggesting that sRAGE 
alone may not guard against TBI.  
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